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The past few years have seen exponential growth
in the psychopharmacology of schizophrenia.
Rapid expansion in the number of therapeutic
agents available to the practicing psychiatrist,
coupled with developments in technologies such
as molecular genetics and brain imaging, have
heralded a new era in the etiology and treatment
of schizophrenia.
These advances have been accompanied by a
huge growth in the amount of related literature
— more than 2000 articles have been published
over the last 12 months. Clearly, this makes it
almost impossible for busy clinicians to keep
up-to-date with the literature.
The Journal of Advances in Schizophrenia and
Brain Research is the answer. The journal provides
psychiatrists with an overview of the recent
literature, along with in-depth reviews of areas
relevant to clinical psychiatry. The journal will
endeavor to bring important issues to the
attention of psychiatrists while ensuring that the
research literature is interpreted in a clinically
meaningful way.
We hope that you will find the Journal of
Advances in Schizophrenia and Brain Research




particular case. He also described a complex interplay
between biological and psychosocial factors, with
psychosocial factors playing a major role in
determining both course and outcome. 
Harding et al. [2] also challenged the earlier
pessimism with a review of the long-term outcome of
subjects who retrospectively met the diagnostic criteria
for schizophrenia. They found an evolution into
productivity and competent functioning in one-half to
two-thirds of cases, rather than the ‘increasing
residual impairment between episodes’ that had been
predicted. Hence, it appeared that not only was the
prognosis for schizophrenia more positive than had
been previously thought, but that the course of
schizophrenia had remained remarkably unchanged
over time. 
Birchwood et al. [3] described a ‘vulnerability–
interaction’ model for schizophrenia, with a vicious
circle of stress, relapse and adverse social effects
leading to further stress and relapse. This interaction
of biological and psychosocial factors produces a
heterogenous disorder with multiple phases and a
varied course and outcome. Psychosocial
interventions aimed at reducing stress, such as
improving coping skills and reducing conflict, alter the
course of the illness.
Three distinct phases of illness can be identified and
each is best suited by different management: 
In the 1960s, most people with severe mental health
problems received long-term care in large mental
hospitals. Since the introduction of de-
institutionalization, more emphasis has been placed on
caring for them in the community and few patients
now receive long-term inpatient care (Fig. 1). 
Early in the 20th century, following the daily
observation of chronic inpatients, schizophrenia was
thought to have a fixed, progressive, deteriorating
course and a principally endogenous genetic cause.
Ciompi [1] challenged this general prognostic
pessimism with his systematic follow-up studies of the
evolution of mental illnesses, initiated in the 1960s. His
review suggested a more positive picture with only
14–24% of schizophrenia patients suffering from
severe chronicity and 24–29% from intermediate
residual symptoms. A total of 53–57% had a favorable
outcome, with 24–33% having only minor residual
symptoms and 20–29% having a complete recovery.
He described an enormous heterogeneity, rather than
uniformity, and challenged the correlation between
genetic loading and outcome, describing a variety of
outcomes for schizophrenia, and great difficulty in










Community Care for Patients with
Schizophrenia — a UK Perspective
Louise Guest and Tom Burns
St George’s Hospital Medical School, London, UK
This article gives an overview of current community treatment used in the maintenance phase of
schizophrenia. It emphasizes the importance of engagement, maintenance medication and social care
as the mainstay of such treatment. It also discusses some more specific interventions, such as
compliance therapy, and psychosocial interventions, such as family work, cognitive behavior therapy
and social skills training, and considers their importance in the prevention of relapse. The merits of
Community Mental Health Teams versus more specialized Assertive Community Treatment Teams are
also discussed. Current issues, including cognitive aspects of schizophrenia, early intervention in
psychosis, and the current controversies surrounding assertive outreach are described. Finally, the
future of community care for schizophrenia is examined.
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• phase 1, the acute phase — characterized by florid
positive psychotic symptoms, with hallucinations,
delusions and high levels of both agitation and
arousal. Inpatient care is often required because of
the nature of the symptoms
• phase 2, the maintenance phase — a mixture of
positive and negative symptoms are present, but
characteristically the level of arousal is reduced. The
patient is usually cared for in the community by a
mixture of outpatient care and community nursing,
with emphasis on the reduction of social stressors
and medication
• phase 3, the recovered phase — characterized by a
decline in positive symptoms and the presence of
some negative symptoms. Patients require only
limited maintenance treatment, the majority of
which can be, and is, offered in primary care settings
by General Practitioners (GPs). 
For the purpose of this article, the authors examine
the community treatment of schizophrenia concentrating
on phase 2, the maintenance phase of care. As indicated,
the patient usually resides in the community at this stage,
although periods of hospitalization may be required
during times of relapse. The main focus of treatment is:
• the supervision and monitoring of mental state
• maintenance medication 
• social care, including occupational activities, help
with accommodation and finances, and family and
carer support. 
Specific psychosocial interventions can be added to
these specific areas.
Contributions of primary care to community treatment
GPs are the only healthcare professionals involved with
many schizophrenia patients [4]. In the 1960s, Murray
Parkes et al. [5] followed-up schizophrenia patients
who had been returned to their relatives or lodgings
after a period of time in a mental hospital. They found
that a greater number of patients received more care
from their GP than from their psychiatrist within the
following year. The main responsibility for day-to-day
care of the discharged schizophrenia patient rested with
the GP, who initiated treatment when the patient
relapsed and was expected to cope with crises at home. 
In 1991, Melzer et al. [6] reported that 1 year after
hospital discharge of patients with schizophrenia into the
community, over half of the patients still had psychotic
mental states. Whilst most patients remained in contact
with either their GP or psychiatrist, they received little
help with any practical issues, such as housing or day
care, and were experiencing ‘revolving door’ patterns of
short, but frequent, hospital admissions. Around the
same time, Kendrick et al. [7] investigated the number
of long-term mentally ill patients on the lists of GPs in
the southwest Thames region of the UK and the
willingness of GPs to take responsibility for them. They
found an uneven distribution of long-term mentally ill
patients, with large numbers localized in Greater London
and within 3 miles of large mental hospitals. Most GPs
were receptive to a care plan shared with psychiatrists.
Importance of maintenance medication
Maintenance medication is the mainstay of treatment
for schizophrenia. A working party of the Section for
Social and Community Psychiatry from the Royal
College of Psychiatrists, London, UK, chaired by
Hirsch, produced a report entitled ‘Psychiatric beds and
resources; factors influencing bed use and service
planning’ [8]. This emphasized the importance of
maintenance medication in the treatment of
schizophrenia, claiming it to be associated with a
reduction in relapse rate and, therefore, a cost-
effective way of utilizing resources for the mentally ill.
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Jolley et al. [9] evaluated the benefits of prescribing
intermittent medication at the first signs of relapse, as
soon as ‘prodromal symptoms’ had been noticed. They
found that the group on intermittent medication
suffered more frequent and prolonged relapses than
the group on continuous prophylaxis, although lower
scores for extrapyramidal side effects were recorded in
the intermittent treatment group. Little adverse effect
on psychosocial functioning was found in the
continuous group, hence confirming the need for
continuous medication in the majority of patients.
The typical antipsychotics, such as chlorpromazine,
haloperidol and thioridazine, cause drowsiness and have
a high incidence of extrapyramidal side effects,
although they suppress symptoms without these side
effects in many patients. The availability of some typical
antipsychotics as depot medication helps improve
compliance because of the regular, but infrequent,
observed dosage. However, this treatment is often not
popular with patients because of the side effects and
the necessary injections. It is imperative that the
minimum required dosage be prescribed, to reduce side
effects, improve tolerance and improve compliance. The
study on compliance by Corrigan et al. [10] cited side
effects of medication and complex treatment regimes as
major barriers to treatment adherence. 
The recent introduction of atypical antipsychotics,
such as olanzapine, quetiapine and risperidone,
associated with fewer side effects, has improved
compliance in those previously intolerant to
conventional antipsychotics. They have, however, made
the monitoring of compliance more difficult since they
are only available in oral form. In some cases, where the
risks of non-compliance with oral medication outweigh
the benefits of the atypical antipsychotics, it may be
pertinent to continue depot medication. 
Clozapine, the prototype atypical antipsychotic, is
now widely used in treatment-resistant schizophrenia.
Two prospective, double-blind, randomized, controlled
trials have shown clozapine to be superior to the typical
antipsychotics in the treatment of schizophrenia [11,12].
However, the risk of neutropenia and agranulocytosis
requires blood monitoring, which again affects
compliance. Despite the relatively high cost, clozapine
may be a cost-effective treatment for resistant
schizophrenia; although there are increased demands on
community resources, these are outweighed by the large
savings associated with reduced hospitalization. 
The effect of antipsychotic medication on cognitive
dysfunction
Cognitive dysfunction is a recognized symptom of
schizophrenia, and has been identified as an important
measure of outcome in the treatment of the disorder. In
addition, antipsychotic drug treatment of schizophrenia
may be complicated by side effects of widespread
dopamine antagonism, including exacerbation of
negative and cognitive symptoms due to frontal cortical
hypodopaminergia. As previously described,
antipsychotic medication is effective in reducing the
positive symptoms of schizophrenia. However, it typically
fails to associate with improvements in cognitive
functioning, and this can result in a failure of the patient
to fully recover to their previous level of functioning and
reintegrate into society. Sharma et al. [13] argue that a
shift in practice towards treatments that aim to improve
cognitive function, rather than focusing on a reduction of
positive symptomatology, is necessary. Clozapine
treatment has been shown to provide a significantly
greater improvement in several aspects of cognitive
function, including attention and verbal fluency, as
compared with typical antipsychotics, and risperidone
appears to have a beneficial effect on working memory. 
Compliance
Since medication only works if it is taken, compliance is
a difficult and important issue in community patients.
There are many reasons for non-compliance, including
denial of illness, apathy and forgetfulness, which can
manifest either as refusal to maintain contact with
healthcare professionals or refusal to take medication.
Corrigan et al. [10] cited side effects, the complexity of
medication regimens, poor understanding of the role of
medication by patients, the poor relationship between
patients and clinicians, and aspects of the service
system, such as long waiting times in clinics, as reasons
for non-adherence to treatment regimens. The study by
Hoge et al. [14] demonstrated that 35% of those who
refused medication cited side effects as their reason,
while doctors thought side effects were important in
only 7% of cases. As mentioned, depot medication has
the advantage of improving compliance as it removes
the daily risk of non-compliance through ambivalence
or forgetfulness. It also removes any debate over
compliance because a non-compliant patient has to
refuse the injection, and hence inform staff and carers
that he/she is not taking medication. This is not the
case with oral medication, since a prescription can be
accepted but disposed of elsewhere without the
knowledge of staff or carers. The observable side effects
of the typical antipsychotics make monitoring of
compliance possible, but the lower side-effect profile of
the atypical antipsychotics makes compliance more
difficult to assess. The fact that the superior atypical
medications are available only in oral form is a distinct
disadvantage in community care. Some teams who
work intensively with patients can offer daily
medication, but this is time consuming. Relatives and
carers can also supervise medication and monitor
compliance, but this can increase the burden on them.
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Kemp et al. [15] recognized that compliance with
antipsychotic medication is an important determinant
of outcome in schizophrenia, and that non-
compliance is a major preventable cause of psychiatric
morbidity. They described compliance as strongly
linked to attitudes to treatment, insight, culture,
treatment response and side effects. Their study
found that a simple brief intervention using
compliance therapy lead to improved compliance, as
compared with non-specific counseling, and that this
was sustainable over time. Compliance therapy is a
cognitive–behavioral approach borrowed from
motivational interviewing, a technique which is used
in a number of medical settings and aims to help
people change their behavior while avoiding
confrontation and stalemate. In compliance therapy,
the approach is brief and pragmatic, providing a more
active therapeutic stance, guided problem solving and
an increased educational component.
Social care
There are various aspects to social care, which are
described in detail below.
Accommodation 
Ensuring adequate accommodation is an important
element of community care. There are various options,
including staffed or unstaffed hostels, group homes,
bedsits and flats, depending on the level of support
required. Supporting patients through liaison with staff,
carers and neighbors plays an important role in
preventing eviction followed by transient
accommodation, such as bed and breakfast, or
homelessness. It is difficult to make contact with
patients who are homeless or in unsupported
environments and living in transient accommodation.
This results in decreased contact, inability to monitor
mental state and, frequently, non-compliance with
medication followed by subsequent decline and relapse. 
Occupation
Ensuring adequate daytime activity is an essential part
of community treatment and helps improve skills,
quality of life and self-esteem. It also reduces stress in
both patients and carers, therefore improving the
overall community tenure of patients. Each patient has
different needs and requirements for activities, ranging
from day hospitals to day centres, sheltered work,
voluntary work and paid employment. With support
and encouragement, patients can work upwards
through the system towards paid employment,
something that is frequently reported as important by
patients. Lehman et al. [16], in their study on
chronically ill patients, cited that unemployment was a
significant area of dissatisfaction and reduced the
quality of life. Offering support, education and advice
to employers can help ensure that employment
continues successfully. 
Family and carer support
The role of family and carers in the community
management of patients who suffer from schizophrenia
cannot be overestimated. With support and education,
carers can offer an alternative to inpatient care. They
play an important role in monitoring mental state and
alerting professionals to signs of deterioration, as well
as supervising and administering medication. Since a
significant number of carers suffer stress and
depression, it is important that they are supported and
not overloaded. The availability of day care and respite
care, and professionals to provide advice and back-up
when required, all helps to support carers. If the carer-
patient relationship is overstretched and breaks down,
the patient may spiral into transient accommodation,
lack of contact and relapse.
Finances
Patients with schizophrenia often suffer financial
hardship due to unemployment, and their inability to
comprehend and navigate the benefit system. Ensuring
adequate income for patients, by assisting with benefit
claims and offering help with budgeting skills, is an
important part of community care [17].
Psychosocial interventions
Following the biological–psychosocial model for the
evolution of schizophrenia described by Ciompi [1], and
the recognized impact of environmental factors and
external stressors, psychosocial interventions have been
accepted as effective treatments for schizophrenia [17].
Psychosocial interventions can be directed towards
difficulties commonly shared with other chronic
illnesses, such as compliance therapy [15] and family
therapy [18,19], or towards areas specific to
schizophrenia, e.g. cognitive therapy for delusions [20].
Family interventions
Brown et al. [18] showed that the relapse rate in young
men who had just recovered from a first episode of
schizophrenia was much higher if they returned to live
with a relative who was prone to make critical
comments. The ill effects of this ‘expressed emotion’
were confirmed by Leff et al. [19] who described that
behavioral family management reduced expressed
emotion in high expressed emotion families, resulting in
a subsequent reduction in relapse rate. Several studies
have confirmed the effectiveness of family treatment in
reducing relapse rate. Hogarty et al. [21] observed a
significant and persistent effect of family intervention on
forestalling relapse by using family therapy to control
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stimuli from the family environment believed capable of
provoking further episodes in vulnerable patients.
Cognitive behavior therapy
Chadwick and Birchwood [21] proposed a cognitive
approach for understanding and treating drug-resistant
auditory hallucinations. Their study demonstrated that
patients hold abnormal beliefs about their voices and
that these beliefs are responsible for their emotional and
behavioral responses to them. They described the
application of the ‘cognitive model of depression’
devised by Beck et al. [23] to these voices, developing a
cognitive behavior therapy strategy of ‘collaborative
empiricism’ [22]. They aimed to reduce the distress
caused by hallucinations rather than the frequency of
them, disputing treatment-resistant delusional beliefs by
‘hypothetical contradiction’ and ‘verbal challenge’, and
‘empirically testing’ the beliefs. Their study
demonstrated an unexpected reduction in hallucinations. 
Social skills training 
The study by Hogarty et al. [21] compared social skills
training with family therapy and drug maintenance
therapy. Social skills training aimed to reduce conflict,
and hence indirectly control stimuli that were believed
capable of provoking a new episode of illness among
vulnerable patients. Their model included social
perception training within both family and extrafamilial
relationships, placing emphasis on strategies to avoid
and reduce conflict with problem solving and requests
for negotiation. Following this intervention, there was
a significant reduction in relapse rate, although the
effect was lost towards the end of the second year of
follow-up. Social skills training is now losing popularity
as a psychosocial intervention. 
Other treatment strategies
Nelson et al. [24] described modifying auditory input,
for instance with a portable cassette player, earplugs or
subvocal counting, as a strategy for decreasing the
severity of auditory hallucinations. Chadwick and Lowe
[20] described ‘belief modification’ as a treatment for
delusions, encouraging patients to view their beliefs as
a reaction to experiences. In therapy, the patient
examined a delusional belief and the arguments for
and against it, with a view to altering the belief.
Problem solving is a general approach used to help
patients manage personal issues and improve coping
skills by identifying problems and targeting specific
problems with identified solutions [25].
Community Mental Health Teams versus Assertive
Community Treatment Teams 
There is a current debate about whether community
patients in the maintenance phase of schizophrenia
should be cared for by specialist teams with particular
skills in dealing with psychotic relapsing patients or by
standard Community Mental Health Teams (CMHTs).
An example of a specialist team is the Assertive
Community Treatment (ACT) Team which was
developed in Madison, WI, USA as an intensive
program of community care, providing a full range of
services within one team and, hence, reducing the
need for other community resources (Table 1) [26].
The team (Fig. 2), which contains essential disciplines
such as nursing, social work, occupational therapy and
psychiatry, delivers the care at the patient’s door
utilizing the ‘in vivo’ approach and assertive follow-up
(reluctance to take no for an answer). This model
demonstrated impressive reductions in hospitalization
and was subsequently replicated by Hoult [27] in
Sydney, Australia. However, Mueser et al. [28]
demonstrated that the differences in favor of ACT have
steadily declined in the USA, and in Europe few studies
have found case management or ACT to make a
significant difference to hospitalization [29]. There is
debate as to whether this is because ACT is not
properly applied in Europe [30] or whether control
services in Europe already contain many elements of
ACT [28]. 
One negative aspect of treating sufferers of
schizophrenia within specialist teams is that treatment
can become depersonalized and more routine. Many
patients are adequately cared for by CMHTs, who have
the skills and resources to care for all but the most
severely ill, unstable ‘revolving door’ patients. It is
therefore pertinent to target ACT at the group of
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Figure 2. The Assertive Community Treatment Team.
Table 1. Components of assertive community
treatment.
• Assertive follow-up
• In vivo approach
• Increased contact frequency
• Emphasis on engagement
• Small caseloads
• Offer psychosocial interventions
JOURNAL OF ADVANCES IN SCHIZOPHRENIA AND BRAIN RESEARCH Vol 3 No 2 2001 39
patients who may otherwise be unmanageable in the
community by virtue of complications such as
substance misuse. 
An international perspective on community care for
patients with schizophrenia
The model of community care described is emulated to a
greater or lesser degree in most of Europe. In Italy, for
example, the move to community care has paralleled
that in UK, with the closure of psychiatric hospitals and
the establishment of Community Mental Health Centers
(CMHCs) [31]. Significantly, the sites of previous
hospitals have been re-utilized as CMHCs and for other
public services, e.g. schools, as well as for flats for the
previous long-stay population. Similar changes have also
been observed in Denmark, with the implementation
and expansion of district psychiatric services, a reduction
in hospital beds and an expansion of both outpatient
services in the immediate environment and social
services in terms of housing and care [32]. In the US,
there has been a move towards community treatment
for schizophrenia since the early 1950s, with a
shortening of hospital stay and substitution of day
hospital treatment, the use of halfway houses for
transitional living and the establishment of Community
Psychosocial Rehabilitation Centres [26].
Special problems
Mobility
Schizophrenia patients are a mobile group prone to
transient accommodation and are therefore difficult to
maintain contact with. Relapse of illness and the
behavioral manifestations of psychosis can precipitate
difficulties with accommodation, making the patient
most difficult to contact when most ill. For this reason,
it is important to ensure secure and stable
accommodation as a vital part of community treatment.
Dual diagnosis
Many patients with schizophrenia also abuse illicit
drugs and alcohol, complicating their illness,
treatment and community care, and significantly
increasing dangerousness and psychiatric morbidity.
Patients with dual diagnosis frequently ‘fall between
two stools’ and do not receive the care that they
need. It is important that problems with drugs and
alcohol are recognized and treated, either by the
CMHT/ACT Team or by referral to a specialist
community drug and alcohol team, with an emphasis
on joint working, communication and liaison between
teams. Teague et al. [33] evaluated a model
integrating key features of ACT with substance abuse
treatment. They found this to be successful and
claimed that, because of the high prevalence of
substance abuse and comorbid mental illness criteria
for substance abuse, treatment should be considered
for more general incorporation into the ACT model.
Current issues
The controversies surrounding Assertive Outreach in
the UK
In the 1980s, concerns were expressed about ‘Care in
the Community’ following several high profile cases of
homicide by people with mental health problems, e.g.
the murder of Jonathon Zito by Christopher Clunis.
The government responded by prioritizing mental
health, with the advent of the National Service
Framework [34], which prioritizes the establishment of
Assertive Outreach Teams. Since this time there has
been a surge of new Assertive Outreach Teams around
the country, working to various models. Many prefer
the ACT approach, which prioritizes the team approach
as an essential component. However there is much
disagreement over which components of the original
model are essential, with continuing debate about
what constitutes a ‘team approach’, a ‘reduced case
load size’, or the necessity for 24-h care. 
The UK700 group published their randomized
control trial of Intensive Case Management (ICM) (one
case manager per 10–15 patients) versus Standard case
mangement (SCM) (one case manager per 30–35
patients) [35]. This study failed to demonstrate a
difference in outcome between the two groups,
causing further confusion. Critics of this study argue
that it lacked program fidelity to the original ACT
model, not using the full team approach or having
small enough caseload size. It has also been proposed
that the control group (SCM) would qualify as an ACT
Team using Teague’s measure of program fidelity [36],
and that this is why no difference in outcome was
found between treatment arms. 
Early detection and intervention of schizophrenia
The processes that make schizophrenia a lifelong
disorder may be most active and do the most damage
early in the course of the disorder [37]. As previously
described, all current treatments for schizophrenia
improve the course of the disorder, but they do not
cure the disorder or alter the persons lifelong
vulnerability to developing psychotic symptoms in the
face of sufficient stress. 
Recent studies of first episode psychosis document
that the average time between onset of psychosis and
first effective treatment is often one year or more. A
current line of theory postulates that active psychosis
may be neurobiologically toxic, either accelerating or
adding to the primary deficit neurobiological processes
that lead initially to onset [38]. Recent studies of first
episode schizophrenia have found significant inverse
correlations between the duration of untreated
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psychosis and better outcome. There is much work to
be done into the development of early detection
systems for schizophrenia, and evaluating the long-
term benefits of reducing the duration of untreated
psychosis with early intervention.
Cognitive function and brain pathology 
Virtually all aspects of cognitive function have been
reported to show impairment in some patients with
schizophrenia, although executive functions [39],
memory functions [40] and various aspects of attention
have been described as especially prone to impairment
[41]. Weinberger et al. [42] examined cerebral blood
flow in patients at rest and during performance of the
Wisconsin Card Sorting Test, a prototypal
frontal/executive task. The schizophrenia patients
performed more poorly than the controls, and this was
mirrored by significantly smaller increases in blood flow
to the prefrontal cortex. However, this finding has not
been consistently replicated, and McKenna [41] found
that over 50% of a sample of acute and chronic
schizophrenia patients showed normal executive
functioning depending on the task used.
A critical review of the structural and functional
cerebral abnormalities found in schizophrenia
concluded that any brain pathology is subtle rather
than gross [43]. It suggests that schizophrenia is
characterized by complex alterations in the normal
reciprocal patterns of activation between anatomically
related areas of the cerebral cortex, rather than by
simple focal reductions in regional brain activity. Easily
the most consistently replicated abnormality in
schizophrenia is lateral ventricular enlargement,
although it does not appear to be associated with any
aspect of the clinical picture and emerges more as a
trait marker for schizophrenia. Crow et al. [44] found
that lateral ventricular enlargement in schizophrenia
was largely restricted to the temporal horns, in
contrast to that seen in Alzheimer’s disease, which was
more generalized. 
Goldberg et al. [45] studied learning and memory in
monozygotic twins discordant for schizophrenia, and
demonstrated that the affected group performed
significantly worse than the discordant group on
various tasks, including story recall, paired association
learning and verbal fluency. The fact that the twin
paradigm had controlled for genome, family
environment and socioeconomic circumstance led
them to conclude that the intercession of the disease
had produced the cognitive deficits in this sample. 
Patients with chronic schizophrenia tend to have
more marked cognitive impairments than acute cases
[46] and it appears that in the minority of cases there is
a progressive decline in cognitive impairment.
However, the majority of evidence suggests that there
is no progressive deterioration in cognitive function in
most patients with schizophrenia over time [47].
Balance of care and liberty
Caring for patients who suffer from schizophrenia in
the community requires the maintenance of a constant
balance between the human rights and liberty of the
patient on one hand and the safety of the patient and
the public on the other. The current UK Mental Health
Act gives us little opportunity to compulsorily treat
patients in the community, other than following a
period of enforced inpatient treatment. This has the
unfortunate consequence of requiring the admission of
patients with the sole purpose of compulsorily
reinitiating treatment, without any other reason for the
restriction of liberty. 
Future of community care in the UK for schizophrenia
The effectiveness of care in the community has been
the subject of great debate. Indeed, due to some high-
profile murder cases, it has been claimed by the media
to have failed despite research findings from the US to
the contrary [48]. A recent prospective 5-year follow-
up study based in London, UK dispelled some of these
myths, providing ‘robust evidence that community care
has worked well for the former patients of psychiatric
hospitals’ [49]. 
The UK government’s current modernization fund for
mental health services [50] is committed to improving
care in the community for schizophrenia patients. It has
prioritized the establishment of Assertive Outreach
Teams to work more intensively with patients to further
reduce risk, categorizing patients with comorbid
substance abuse as a high-risk group. A proposed
revision of the UK Mental Health Act was sent out for
consultation in late 1999 [51]. Controversially, it
proposes a community treatment order, and is the
source of much current debate. Proponents of the order
argue that, if introduced, it would have an enormous
effect on community treatment and care, making it
more tenable and further reducing risk and the need for
hospitalization. Conversely, opponents argue that it
would constitute a further erosion to the civil liberties of
the mentally ill [52]. Either way, the improvement of
community care for people with schizophrenia is set to
remain high on the current agenda.
References
1. Ciompi L. Learning from outcome studies. Toward a
comprehensive biological-psychosocial understanding of
schizophrenia. Schizophr Res 1988;1:373–84.
2. Harding CM, Brooks GW, Ashikaga T et al. The Vermont
longitudinal study of persons with severe mental illness, II: Long-
term outcome of subjects who retrospectively met DSM-III
criteria for schizophrenia. Am J Psychiatry 1987;144:727–35.
JOURNAL OF ADVANCES IN SCHIZOPHRENIA AND BRAIN RESEARCH Vol 3 No 2 200140
LOUISE GUEST AND TOM BURNS
3. Birchwood M, Hallet S, Preston M. Schizophrenia. An Integrated
Approach to Research and Treatment. London: Longman, 1988.
4. Goldberg D, Huxley P. Mental Illness in the Community.
London: Tavistock, 1980. 
5. Murray Parkes C, Brown G, Monck E. The general practitioner
and the schizophrenic patient. Br Med J 1962;1:972–6.
6. Melzer D, Hale AS, Malik SJ et al. Community care for patients
with schizophrenia one year after hospital discharge. BMJ
1991;303:1023–6.
7. Kendrick T, Sibbald B, Burns T et al. Role of general 
practitioners in care of long term mentally ill patients. BMJ
1991;302:508–10.
8. Hirsch S. Psychiatric beds and resources, factors influencing bed
use and service planning. Report for the Royal College of
Psychiatrists. Gaskell, 1998.
9. Jolley AG, Hirsch SR, Morrison E et al. Trial of brief intermittent
neuroleptic prophylaxis for selected schizophrenic outpatients:
clinical and social outcome at two years. BMJ 1990;301:837–42.
10. Corrigan PW, Liberman RP, Engel JD. From noncompliance to
collaboration in the treatment of schizophrenia. Hosp
Community Psychiatry 1990;41:1203–11.
11. Kane J, Honigfeld G, Singer J et al. Clozapine for the treatment-
resistant schizophrenic: A double-blind comparison with
chlorpromazine. Arch Gen Psychiatry 1988;45:789–96.
12. Breier A, Buchanan RW, Kirkpatrick B et al. Effects of clozapine
on positive and negative symptoms in outpatients with
schizophrenia. Am J Psychiatry 1994;151:20–6.
13. Sharma T, Mockler D. The cognitive efficacy of atypical
antipsychotics in schizophrenia. J Clin Psychopharmacol
1998;18:12S–9.
14. Hoge SK, Appelbaum PS, Lawlor T et al. A prospective,
multicenter study of patients’ refusal of antipsychotic
medication. Arch Gen Psychiatry 1990;47:949–56.
15. Kemp R, Hayward P, Applewhaite G et al. Compliance therapy in
psychotic patients: randomised controlled trial. BMJ
1996;312:345–9.
16. Lehman AF, Ward NC, Linn LS. Chronic mental patients: the
quality of life issue. Am J Psychiatry 1982;139:1271–6.
17. Kane JM, McGlashen TH. Treatment of schizophrenia. Lancet
1995;346:820–5.
18. Brown G, Monck E, Carstairs G et al. Influence of family life on
the course of schizophrenia. Br J Preventative Social Med
1962;16:55–68.
19. Leff J, Kuipers L, Berkowitz R et al. A controlled trial of social
intervention in the families of schizophrenic patients. Br J
Psychiatry 1982;141:121–34.
20. Chadwick PD, Lowe CF. Measurement and modification of
delusional beliefs. J Consult Clin Psychol 1990;58:225–32.
21. Hogarty GE, Anderson CM, Reiss DJ et al. Family
psychoeducation, social skills training, and maintenance
chemotherapy in the aftercare treatment of schizophrenia. II.
Two-year effects of a controlled study on relapse and
adjustment. Environmental-personal Indicators in the Course of
Schizophrenia (EPICS) research group. Arch Gen Psychiatry
1991;48:340–7.
22. Chadwick P, Birchwood M. The omnipotence of voices. A
cognitive approach to auditory hallucinations. Br J Psychiatry
1994;164:190–201.
23. Beck A, Rush A, Shaw B et al. Cognitive Therapy of Depression.
New York: Guilford, 1979.
24. Nelson HE, Thrasher S, Barnes TR. Practical ways of alleviating
auditory hallucinations. BMJ 1991;302:327.
25. Hawton K, Kirk J. Problem solving. In: Hawton K, Salkovskis P,
Kirk J et al, editors. Cognitive Behaviour Therapy for Psychiatric
Problems. Oxford: Oxford University Press, 1989.
26. Stein LI, Test MA. Alternative to mental hospital treatment. I.
Conceptual model, treatment program, and clinical evaluation.
Arch Gen Psychiatry 1980;37:392–7.
27. Hoult J. Community care of the acutely mentally ill. Br J
Psychiatry 1986;149:137–44.
28. Mueser KT, Bond GR, Drake RE et al. Models of community care
for severe mental illness: a review of research on case
management. Schizophr Bull 1998;24:37–74.
29. Holloway F, Oliver N, Collins E et al. Case management: A critical
review of the outcome literature. Eur Psychiatry 1995;10:113–28.
30. Marshall M, Lockwood A. Assertive community treatment for
people with severe mental disorders (Cochrane review). In: The
Cochrane Online Library,1998.
31. Ramon S, Grazia Giannichedda M. Psychiatry in Transition: The
British and Italian Experiences. Great Britain: Pluto Press, 1991.
32. The Ministry of Health. Health care in Denmark. Copenhagen:
The Ministry of Health, 1999.
33. Teague GB, Drake RE, Ackerson TH. Evaluating use of continuous
treatment teams for persons with mental illness and substance
abuse. Psychiatr Serv 1995;46:689–95.
34. Department of Health. National Service Framework for Mental
Health – Modern Standards and Service Models. London:
Department of Health, 1999.
35. Burns T, Creed F, Fahy T et al. Intensive versus standard case
management for severe psychotic illness: a randomised trial. UK
700 Group Lancet 1999;353:2185–9.
36. Teague GB, Bond GR, Drake RE. Program fidelity in assertive
community treatment: development and use of a measure. Am J
Orthopsychiatry 1998;68:216–32.
37. McGlashen TH. Early detection and intervention of schizophrenia:
rationale and research. Br J Psychiatry 1998;172:3–6.
38. Wyatt RJ. Neuroleptics and the natural course of schizophrenia.
Schizophr Bull 1991;17:325–51.
39. Goldberg TE, Weinberger DR, Berman KF et al. Further evidence
for dementia of the prefrontal type in schizophrenia? A controlled
study of teaching the Wisconsin Card Sorting Test. Arch Gen
Psychiatry 1987;44:1008–14.
40. McKenna PJ, Tamlyn D, Lund CE et al. Amnesic syndrome in
schizophrenia. Psychol Med 1990;20:967–72.
41. McKenna PJ. Schizophrenia and the related syndromes. Oxford:
Oxford University Press, 1994.
42. Weinberger DR, Berman KF, Zec RF. Physiological dysfunction of
dorsolateral prefrontal cortex in schizophrenia. I. Regional
cerebral blood flow evidence. Arch Gen Psychiatry
1986;43:114–24.
JOURNAL OF ADVANCES IN SCHIZOPHRENIA AND BRAIN RESEARCH Vol 3 No 2 2001 41
COMMUNITY CARE FOR PATIENTS WITH SCHIZOPHRENIA — A UK PERSPECTIVE
43. Chua SE, McKenna PJ. Schizophrenia – a brain disease? 
A critical review of structural and functional
cerebral abnormality in the disorder. Br J Psychiatry
1995;166:563–82.
44. Crow TJ, Ball J, Bloom SR et al. Schizophrenia as an anomaly of
development of cerebral asymmetry. A postmortem study and a
proposal concerning the genetic basis of the disease. Arch Gen
Psychiatry 1989;46:1145–50.
45. Goldberg TE, Torrey EF, Gold JM et al. Learning and memory in
monozygotic twins discordant for schizophrenia. Psychol Med
1993;23:71–85.
46. Liddle PF, Crow TJ. Age disorientation in chronic schizophrenia is
associated with global intellectual impairment. Br J Psychiatry
1984;144:193–9.
47. Klonoff H, Fibiger CH, Hutton GH. Neuropsychological patterns
in chronic schizophrenia. J Nerv Ment Dis 1970;150:291–300.
48. Lamb HR. Lessons learned from deinstitutionalisation in the US.
Br J Psychiatry 1993;162:587–92. 
49. Trieman N, Leff J, Glover G. Outcome of long stay psychiatric
patients resettled in the community: Prospective cohort study.
BMJ 1999;319:13–6.
50. Department of Health. Modernizing Mental Health Services.
London: Department of Health, 1999.
51. Secretary of State for Health. Reform of the Mental Health Act
1983 - Proposals for Consultation. London: The Stationary
Office, 1999.
52. Moncrieff J, Smyth M. Community treatment orders – a bridge
too far? Psychiatric Bulletin 1999;23:644–6.
JOURNAL OF ADVANCES IN SCHIZOPHRENIA AND BRAIN RESEARCH Vol 3 No 2 200142
LOUISE GUEST AND TOM BURNS
During the 6 years since the clinic was established
these criteria have been refined and tested so that we
have a transition rate of 41% within a 12-month
period. Now we are extending our focus, utilizing our
selection criteria to investigate biological and
psychological risk factors for psychotic illness. This
paper discusses the evolution of the concepts and
strategies we have used at PACE for studying young
people at ultra-high risk of developing psychosis, and
concludes with the application of these methods to
investigate risk factors for psychosis.
The concept of prodrome versus ‘at risk mental state’
The term prodrome has been used in the majority of
studies that have focused on the period directly
preceding the onset of psychosis where a change in
mental state is first recognized. This term is largely
retrospective in nature, as it has been traditionally
applied only after acute psychosis has developed [1]. As
a result, studies that have investigated the prodromal
period have also been of a retrospective nature and
may have been affected by recall bias and ‘effort after
meaning’ [2]. Prodrome has also been used to refer to
The mental healthcare focus on prevention and
intervention has made the psychotic prodrome
increasingly important. The conceptualization of this
illness phase has changed with the development of
strategies that make its study possible — it has
become a prospective rather than a retrospective
term. At the Personal Assessment and Crisis
Evaluation (PACE) clinic we have been refining
methods for identifying individuals who are at ultra-
high risk of developing psychosis. Our clinical criteria
utilize a ‘close-in’ strategy, which maximizes the
transition rate to psychosis. Clients can be in one of
three groups:
• those with attenuated symptoms
• those with transient psychotic symptoms that
spontaneously remit









Prediction and Intervention in the
Pre-Psychotic Phase
Katherine N Thompson, Patrick D McGorry, Lisa J Phillips and Alison R Yung
PACE Clinic, Parkville, Victoria, Australia
The psychotic prodrome is an important illness phase that has until recently only been accessible
retrospectively. At the Personal Assessment and Crisis Evaluation (PACE) clinic, our research has
suggested that it is possible to identify young people at ultra-high risk of developing psychosis and to
monitor them both prior to and during the onset of psychosis. We suggest that ‘at risk mental state’ is
a more appropriate term for the prospective study of this illness phase. Through research at our clinic
we have developed clinical criteria for identifying this ultra-high-risk group, with a ‘close-in’ strategy
that reduces the amount of time required for follow-up before the transition to psychosis. In our
largest published study to date the transition rate was reported to be 41%. This suggests that our
criteria detect those at risk of psychosis, which allows future development of treatment that may delay
or prevent psychosis, as well as reducing the duration of untreated psychosis. This could have long-
term health benefits for both individuals and the community, and could reduce the overall impact of
such illnesses in vulnerable young people. This unique patient group also allows the study of risk
factors for illnesses such as schizophrenia, without the confounding effect of medication and acute
symptomatology that is a constant problem in chronic and first-episode patient groups.
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the period immediately preceding relapse of acute
psychosis in individuals with an already established
illness. Due to the retrospective nature of this concept,
and the potential confusion in the use of this term, we
suggest the use of ‘relapse prodrome’ to describe the
period before psychotic relapse, and the use of ‘at risk
mental state’ as a more appropriate term for
prospective psychosis prediction [2].
There are a number of reasons for the use of ‘at risk
mental state’. This term takes into account that not all
the clients who come to the PACE clinic will make the
transition to psychosis. Rather than taking the view
that the prodrome is the earliest form of psychosis, and
is therefore inevitable, the new term recognizes this
mental state as conferring a heightened vulnerability to
developing psychosis [2]. The distinction between
these views is important because the former takes for
granted that transition to psychosis will occur, whereas
the latter recognizes that being ‘at risk’ results from a
number of reasons, including family history and stress,
and may be avoided through a change in circumstance
or via clinical intervention and/or treatment [3,4]. The
use of ‘at risk mental state’ is also conceptually
different to the notion of schizotaxia [5]. It is not
confined to being an unexpressed genetic
predisposition because, in our model, risk factors do
not require a family history of psychosis.
The implication of using ‘at risk mental state’ is that
vulnerable individuals can now be studied
prospectively, and the changes in psychopathology and
biological variables that coincide with the transition to
psychosis can be monitored [3,4]. It also enables a
‘close-in’ strategy to be used [1]. This involves
combining risk factors to enhance the number of true
positive cases; thereby reducing the follow-up period
required to observe transition [2].
A number of ethical issues have been raised in
relation to the prospective study of ‘at risk’ individuals.
The first is the perceived danger of including false
positives in the PACE clinic and related research
program [2]. While some individuals appear to have
similar characteristics to clients who go on to develop
acute psychosis, they may not make the transition. It
was originally thought that these individuals would be
unnecessarily exposed to stigma, and the medical
labeling of their presenting problems. However,
experience with our client group has shown that many
are aware of their risk of developing a psychotic illness
and would like to discuss it, particularly if another
family member is unwell. Provided that information is
given in a sensitive manner, discussion of risk can be
positive and health promoting [3]. The potential
benefits of this strategy outweigh the risks, and may
contribute to a reduction in the duration of untreated
psychosis, a better outcome and lower relapse rates in
people who develop an illness. In others it may delay
transition and reduce the disability associated with
their presenting symptoms.
Clinical criteria for detecting ‘at risk mental states’
In a series of studies, our center has developed and
refined criteria that make it possible to identify young
people at ultra-high risk of developing psychosis. These
criteria have been actively used in the PACE clinic since
1994, and were originally applied to individuals aged
between 16 and 30 years — a time that corresponds to
the period of maximum risk. More recently we have
changed this age range to individuals between 14 and
30 years of age [1]. Our criteria for identifying ‘at risk
mental states’ have evolved with experience. We
currently accept people into our clinic if they belong to
one of three groups:
• an attenuated symptom group
• a brief limited intermittent psychotic symptom group
• a state or trait risk factor group, i.e. clients that have
a decrease in functioning and a first degree family
member with a psychotic illness [1].
Inclusion and exclusion criteria for these groups are
based on the Brief Psychiatric Rating Scale (BPRS) [6]
and the Global Assessment of Functioning (GAF) rating
scale [7].
Group 1 consists of people experiencing attenuated
symptoms. These symptoms may include ideas of
reference and magical thinking (BPRS rating 2–3 on
unusual thought content), perceptual disturbances
(BPRS rating 1–2 on hallucinations), paranoid ideation
(BPRS rating 1–3 for suspiciousness), or odd speech
(BPRS rating 1–3 on conceptual disorganization) [1,8].
These symptoms need to be held with a reasonable
amount of conviction, and occur several times per
week during the past year, but for no longer than 5
years [8,9].
Group 2 consists of people that have experienced
Brief Limited Intermittent Psychotic Symptoms (BLIPS).
These may include ideas of reference, magical thinking,
perceptual disturbance, paranoid ideation and odd
speech, but will exceed the rating threshold used in the
attenuated group [1,8,9]. Therefore, the severity of
symptoms would also exceed the threshold for
psychosis. However, the duration of the ‘BLIP’ has to
be less than one week, and the symptoms need to
have spontaneously resolved. The BLIP is required to
have happened within the 5 years before referral to
the PACE clinic [8,9].
Group 3 consists of people with trait and state risk
factors. These people have a first degree relative with
a psychotic disorder, including diagnoses of
schizophrenia, schizoaffective disorder or bipolar
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disorder, in a parent or sibling [1,8,9]. In addition, they
need to have experienced a marked reduction in
functioning of 30 points or more on the GAF from
premorbid level, within the last year [8,9].
Subjects are excluded from the PACE clinic if they
have an intellectual disability, a known organic
disorder, poor English skills, a history of acute psychosis
or treatment with neuroleptics [8,9].
Clients are considered to have made the transition
to psychosis according to BPRS scores [6]. Clients need
to have one of the following:
• a BPRS score of 3 or more on the hallucination item
• a score of 4 or more on the unusual thought
content item
• a score of 4 or more on the formal thought
disorder item. 
These symptoms need to occur several times per
week, with the change of mental state persisting for
more than 1 week [8,9].
In our largest study to date, 49 subjects were
followed-up monthly for a 12-month period, 41% of
these young people made the transition to psychosis
within this time period [8,9]. Many of these clients
developed psychosis within the first few months after
referral to our service. The people who participated
were referred to the clinic over a 16-month period. In
total we received 119 referrals from a variety of
services including school and university counselors,
general practitioners, council youth programs and our
own first-episode psychosis triage team [1]. Out of
these referrals, 73 were seen for an initial interview,
and 49 met our criteria. The remaining referrals were
either deemed unsuitable by telephone screening, or
failed to attend their appointment. Distribution of
these 49 young people with an ‘at risk mental state’
across the three inclusion groups is shown in Fig. 1.
The results of this study suggest that it is possible to
identify ‘at risk mental states’ using our clinical criteria,
and highlight the importance of raising community
awareness of our service to facilitate referrals.
We have since revised our inclusion and exclusion
criteria so that it is no longer reliant on BPRS ratings.
Instead, we have implemented new criteria based on
the Comprehensive Assessment of At Risk Mental
States (CAARMS), an instrument that we have been
developing in the clinic over a number of years, with
the specific purpose of monitoring ‘at risk mental
states’. The new symptom threshold for psychosis
requires the presence of bizarre (thought broadcasting)
or non-bizarre (paranoia) beliefs that are held with
delusional conviction, or hallucinations that the subject
believes are true and very distressing, or lack of
coherence or speech with loose associations. The
minimum frequency of these symptoms is either at
least three times per week for a minimum of 1 h, or
more frequently for a shorter duration. The symptoms
need to be present for more than 1 week.
Current and future research directions within PACE
Having established criteria that we know reliably
identify young people at ultra-high risk of developing
psychosis, with a good transition rate, we have begun
to develop a research focus on psychological and
biological risk factors for psychosis [3], as well as
preventative treatments. In light of the heterogeneity of
schizophrenia and other psychoses it is unlikely that one
factor alone predisposes a person to develop this illness.
Instead, a number of factors combine to increase a
person’s vulnerability threshold. Much of the research in
illnesses such as schizophrenia to date has been
confounded by the effect of neuroleptic medication.
Therefore, the PACE sample of young people at ultra-
high risk of psychosis presents us with a unique
opportunity to investigate biological and psychological
risk factors without the influence of medication, and
without the presence of acute psychosis. In this way we
can study the biological changes associated with the
transition to psychosis and/or the abnormalities in
various systems that may have been present prior to
illness onset. We can also investigate whether early use
of preventative treatments may delay or prevent the
transition to psychosis.
The ultimate goal of establishing a clinic such as
PACE is not only to develop reliable ways of identifying
at risk young people, but also to use this information
to develop preventative strategies to reduce the
development of disorders such as schizophrenia. In the
period between 1996 and 1999 we conducted a
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Figure 1. Number of patients in each intake
group, according to our criteria. The number of
patients who made the transition to psychosis is
indicated in brackets.










randomized controlled trial that combined cognitive
behavioral therapy and neuroleptic treatment, with
supportive therapy. Out of a total of 60 patients that
agreed to randomization, 35.7% (10/28) of the
supportive case management group made the
transition to psychosis within the 6 months of
treatment, whereas only 12.5% (4/32) of patients in
the cognitive therapy and risperidone group became
psychotic [10]. The difference in the transition rate
between these two groups was significant. Although
not finalized, data from a 12-month follow-up
suggests that more of the patients in the cognitive
therapy and risperidone group have become psychotic
after treatment ceased. This may indicate that a longer
treatment period is necessary [11].
We are currently commencing another randomized
trial at PACE that is double-blinded. Patients that
consent to participate will receive a combination of
treatments, both antipsychotic and therapy based. As
with the previous study, it is hypothesized that
preventative treatment will reduce the rate of
transition in young people at ultra-high risk of
developing psychosis. In this way we hope to
determine treatments that may be suitable for this
group, whether they be therapy based or biological
through medication [11]. Given the 41% transition
rate found in one of our previous studies, we
hypothesize that these treatments will decrease the
transition rate to psychosis.
Our preliminary findings concerning biological and
psychological risk factors for psychosis have suggested
that our ultra-high-risk group have significantly larger
left hippocampi compared with controls [9]. There was
no significant difference on the right side. A Cox
regression analysis showed that greater left
hippocampal volume in this group was predictive of
transition. These findings suggest that hippocampal
volume reduction may occur during the transition from
high risk to first-episode psychosis because previous
magnetic resonance imaging studies have reported
hippocampal reduction in chronic and first-episode
psychosis patients [9,12]. Other variables that we have
studied include neurocognitive testing and
developmental risk factors, such as prenatal
complications. These were not found to be associated
with onset of psychosis. However, maternal age of
more than 30 years and cannabis dependence were
associated with an increased risk of transition [11]. As
a whole, these tests have not shown a high specificity
or sensitivity for psychosis (Table 1).
We are currently investigating the role of stress on
transition to psychosis. This study measures diurnal
hypothalamic-pituitary-adrenal axis function, and
employs a more intensive combined dexamethasone
and corticotrophin releasing factor test. These
measures have been obtained at intake to the clinic,
for a period of 12 months, or until the transition to
psychosis is made, whereupon the initial tests are
repeated. A general psychopathology interview is
performed to compliment these measures. MRI scans
at intake and then at 12 months, or at transition,
complete the study. This gives a comprehensive
assessment of how stress may be involved in the onset
of psychosis. A pilot version of this study will be
complete at the end of 2000, with a larger scale study
commencing in 2001 and continuing for 3 years.
In addition to the studies reported thus far, we are
investigating other indices such as neurological soft
signs, neurocognitive tests, and a wider range of
hormones. Taken together, our research has the
potential to develop effective treatments that can
delay or prevent the onset of psychosis in vulnerable
individuals and, with the identification of biological
risk factors, it could give a valuable insight into the
development process of illnesses such as
schizophrenia [11].
Summary
Our research at the PACE clinic suggests that it is
possible to identify young people at ultra-high risk of
developing psychosis. These young people can be
monitored prospectively, with a high likelihood that
many of them will make the transition to psychosis
within a 12-month period, according to our clinical
criteria. The transition rate of 41% found in our first
study has made it feasible to use this ability to identify
‘at risk mental states’ to study psychological and
biological risk factors for psychosis, as well as allowing
a focus on prevention. In the long-term, this mental
health strategy may reduce or delay the debilitating
effects of illnesses such as schizophrenia, and direct
resources to a period of illness that has the potential to
return the maximum benefit for the patient and the
community [3,11].
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Table 1. Predictors of psychosis in the PACE sample.
Duration of symptoms >900 days
GAF score <51
BPRS total score >15 
BPRS psychotic subscale score >2 
SANS attention score >1
HRSD score >18
Normal left hippocampal volume
Cannabis dependence
Maternal age >30 years 
BPRS: Brief Psychiatric Rating Scale; GAF: Global Assessment of
Functioning; HRSD: Hamilton Rating Scale for Depression; PACE:
Personal Assessment and Crisis Evaluation; SANS: Scale for
Assessment of Negative Symptoms.
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• vergence: for tracking a visual target that is moving
towards or away from the observer. 
Abnormalities of smooth pursuit eye movement in
patients with schizophrenia were first reported by
Diefendorf and Dodge [7], but emerged as a promising
biological marker for the disease in the 1970s [8,9]
following the demonstration of abnormalities in family
and twin studies. Abnormalities of smooth pursuit eye
movements are reliably associated with both adult and
childhood forms of schizophrenia [10].
Saccadic eye movements
Two major types of rapid eye movements (saccades) can
be distinguished: reflexive (or visually-guided) saccades,
and voluntary (or internally-guided) saccades [11]. A
reflexive saccade can be defined as an automatic
orienting response to a novel event in the peripheral
field. This requires the integration of spatial attention,
visual encoding, and a precisely targeted motor
program, but places few demands on higher-order
executive functions. For voluntary paradigms, there is an
increased demand on higher order cognitive resources,
which results in an increased complexity in the pattern
of brain activation. The ability to resist a prepotent
stimulus, and to generate an action that is based on a
Information processing and the voluntary control of
action are mediated by the precise control of visual
attention to specific objects and to events in the
environment. The focus of attention is most readily
reflected by the line of sight as determined by the
oculomotor system [1]. However, neurocognitive
research in schizophrenia has largely been restricted to
traditional psychological tests of cognition. In recent
years, research on eye movement behavior has
provided an alternative index of high-level cognitive
functions. In schizophrenia research, abnormalities of
smooth pursuit eye movements have been a primary
focus of research, and are widely proposed as a
potential biological marker of this disease [2–6]. Slow
eye movements include:
• smooth pursuit: for tracking a visual target that is
moving smoothly across the environment 
• vestibulo-ocular reflex: for maintaining steady
fixation of an image on the retina during a head or
body rotation by generating an equal and opposite











B Recent Saccadic Eye Movement
Research Uncovers Patterns of Cognitive
Dysfunction in Schizophrenia 
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The frontal cortex and the subcortical areas of the brain play a major role in the control of thought and
action. Eye movements are increasingly used in neuropsychological research to explore the executive
and sensorimotor functions of such neural networks. This interface links the control of action, at the
fundamental levels of neurophysiological and neurochemical processes, with the high-level cognitive
operations that underlie visual orienting. Patients with schizophrenia have neurocognitive impairments
that can be readily investigated with novel saccadic eye movement paradigms. Animal, human lesion,
and neuroimaging studies have identified the cerebral centers that underlie saccadic eye movements.
The areas of the prefrontal cortex include the dorsolateral prefrontal cortex, the frontal eye fields, the
supplementary eye fields, and the anterior cingulate gyrus. Pathology of saccadic eye movements
therefore provides information on the functional status of the underlying neural circuitry in brain
disorders such as schizophrenia.
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cognitive analysis of the task, can be evaluated with the
memory-guided and the anti-saccade paradigms where
an impulsive response will impede performance (Fig. 1).
The control of eye movements therefore incorporates
the integration of visuospatial information and high-
level cognitive operations in a complete behavioral
system. By using a battery of paradigms [12,13], it has
been possible to dissociate key cognitive operations and
thus identify distinctive abnormalities in the behavioral
profiles of saccadic eye movements (Table 1).
The programing of a voluntary saccade is the product
of a multilevel network of sensorimotor processors and
cognitive subsystems. The cerebral centers underlying
saccades are known from primate, human lesion, and
neuroimaging studies. Several areas of the prefrontal
cortex have been identified including the dorsolateral
prefrontal cortex, the frontal eye fields, the anterior
cingulate gyrus, and the supplementary eye fields [14].
Detailed neurophysiological research in animals [15–17]
and neurological eye movement studies in Parkinson’s
disease [18–20] have elucidated the functions of the
nigrostriatal dopaminergic pathways in the control of
saccadic eye movements (Fig. 2). 
Inhibitory control in schizophrenia
The anti-saccade paradigm [21] is used widely to
explore the programing of volitional eye movements
and the inhibition of inappropriate action. Correct anti-
saccades are directed towards a spatial position in the
opposite visual field to that of the stimulus (Fig. 1b).
The paradigm requires suppression of the reflexive
saccade that would normally be generated in response
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Figure 1. Saccadic paradigms. A: A visual stimulus is presented in a random sequence to the left or right of a
central fixation point; subjects are instructed to respond with a rapid and accurate eye movement. B: Anti-
saccades are directed towards a spatial position in the opposite visual field to that of the stimulus. The paradigm
requires suppression of the reflexive saccade that would normally be generated in response to a novel visual
target, and the generation of a volitional saccade to the opposite hemifield. C: Subjects are instructed to
suppress the normal reflexive eye movement in response to a novel stimulus, and to delay the saccade until the
offset of the central light. There is no visual information on the location of the previously presented target at the
moment of saccadic initiation. D: A visible target steps between (two) fixed locations in a predictable temporal
sequence. In some studies there is an additional phase where a series of visible targets is followed by a sequence





to a novel visual target, and the generation of a
volitional saccade to the opposite side.
There is a general consensus on the increased
frequency of inhibition errors in schizophrenic
patients; a consensus that is striking in the context of
schizophrenia research [13,22–36]. The dramatic
impairment of saccadic distractibility in schizophrenia
is also evident in other volitional eye movement tasks,
such as the memory-guided movements. The
abnormality is correlated with errors of perseveration
on the Wisconsin Card Sort Test, which is consistent
with the view of prefrontal lobe dysfunction in
schizophrenia [29]. This is supported by the similar
pattern of saccadic impairment with a unilateral lesion
of the dorsolateral prefrontal cortex [37]. Chronic [12]
and first-episode patients with schizophrenia [38]
show a similar severity of disturbance on this task.
Functional brain imaging studies with PET [39] and
SPET [24] have revealed that the cortical centers
underlying the abnormality include the dorsolateral
prefrontal cortex, the anterior cingulate, the
neostriatum, and the temporal cortex.
Negative symptoms such as anergia, deficit
syndrome and formal thought disorder are associated
with poor anti-saccade performance, whereas this is
not true for positive symptoms [12,25,26,31].
Patients with tardive dyskinesia (TD) generate more
inhibition errors than patients without TD [40].
Treatment with conventional antipsychotic
medication [12,30,31] appears to have no effect on
anti-saccade error rates [12].
Dopaminergic systems and eye movements 
The hypothesis that volitional eye movements are a
sensitive behavioral marker of dopamine receptor
function in nigrostriatal projections is supported by
extensive research in animal studies [41–44] and
Parkinson’s disease [18–20,45]. The pattern of eye-
movement changes produced corresponds to those
found in schizophrenic and bipolar patients on typical
neuroleptics. These abnormalities are most severe in
patients with increased extrapyramidal symptoms [12],
suggesting an effect that is related to dopamine
depletion within the nigrostriatal pathways.
Eye-movement measures proved to be the most robust
predictor of neuroleptic status, and were superior
to conventional psychiatric and extrapyramidal
rating scales [12]. 
Animal studies have supported these findings by
showing that the dopaminergic neurotoxin 1-methyl-
4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) in the
neostriatum induces a specific abnormality in memory-
guided saccadic eye movements [42,43]. Effects on
volitional saccadic eye movements requiring working
memory have also been shown to be acutely sensitive
to a D1-antagonist in the prefrontal cortex [44]. A D1-
antagonist impairs performance in a dose-related
manner in the delayed oculomotor task (a task
analogous to the memory-guided task used in man).
The effect in monkeys does not appear with D2- or D3-
antagonists, which suggests that the effect is specific
to frontal lobe D1-receptors. 
The neuroreceptors that mediate the abnormality in
schizophrenia are unclear, though some recent clinical
data indicate that the 5-HT2 receptor may play a
critical role [46,47]. This distractibility of visual
attention and eye movement is not reversed by
treatment with conventional neuroleptics. The effects
of the ‘newer’ atypicals are currently under evaluation
in a number of laboratories. 
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Figure 2. Neural control of anti-saccades.
BG: basal ganglia; BS: brain stem; DLPFC: dorsolateral prefrontal
cortex; FEF: frontal eye fields; LGB: lateral geniculate body; OCC:
occipital cortex; PEF: parietal eye field; PPC: posterior parietal
cortex; SC: superior colliculus; SEF: supplementary eye fields.









Table 1. Dissociation of two key operations in the
saccadic paradigms. The ability to inhibit reflexive
glances and the ability to perform actions based on
spatial working memory can be assessed separately
by combining four saccadic paradigms.
Inhibition Spatial working
of target memory
Visually-guided saccades – –
Anti-saccades + –
Memory-guided saccades + +
Predictive saccades* – +
*No-vision target phase (see Fig. 1)
+ : Cognitive operation requires high priority for correct
performance
– : Cognitive operation requires low priority for correct
performance 
Anti-saccade abnormality as a biological marker in
genetic research
Measures of oculomotor performance are among the
most promising endophenotypes for schizophrenia, and
are becoming increasingly applied as biological markers
in genetic research [48,49]. The abnormal frequency of
inhibition errors in the anti-saccade paradigm rarely
occurs in the general population, but is strongly
correlated with the presence of schizophrenia (although
distinct from active psychotic symptoms). Recent
studies with the families of schizophrenic patients have
detected the abnormality in non-psychotic biological
relatives and have demonstrated a link to the presence
of the abnormality in the probands. Probands with high
levels of inhibition errors were more likely to have
relatives who also displayed the anti-saccade
abnormality than probands with normal performance
[36,50,51]. Using an analytical model based on anti-
saccade inhibition errors, an impressive risk ratio for
non-psychotic first degree relatives was achieved and
70% of patients were correctly classified [34]. Anti-
saccade inhibition errors were increased in first, but not
second-degree relatives [50], which is consistent with
the genetic inheritance patterns in schizophrenia [52]. 
Conclusions
In recent years there has been a growing interest
in eye movement abnormalities in schizophrenia,
demonstrated by several publications. Saccadic
paradigms now supplement the more traditional
methods of cognitive research. Research strategies that
examine a profile of saccade performance across a
range of saccadic eye movement tests can target
different neuropsychological operations. The anti-
saccade and the memory-guided saccade paradigm, in
particular, are increasingly used to probe selective
neurocognitive operations. Current developments
suggest that research programs incorporating a battery
of saccadic paradigms combined with neuroimaging,
clinical and psychopathological observations are likely
to become more characteristic of future developments,
and will provide an important tool in unraveling the
pathophysiology of this mysterious disorder. 
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Commentary and Analysis on Recent Key Papers
BASIC PHARMACOLOGY
Restoration of latent inhibition by olanzapine but not
haloperidol in entorhinal cortex-lesioned rats
Coutureau E, Gosselin O, Di Scala G.
Psychopharmacology 2000;150:226–32.
Latent inhibition (LI) is the detrimental effect of
pre-exposure of a to-be-conditioned stimulus (CS)
on its future ability to enter into a conditioned
association. It has been intensively studied both
in animals and in humans, and is considered a
relevant animal model for the study of the biological
bases of schizophrenia.
Studies in rats have previously shown that disruption
of LI is due to the release of dopamine in the nucleus
accumbens [1]. Coutureau et al. [2] recently observed
that lesions of the retrohippocampal area, comprising
the subiculum and the entorhinal cortex, also disrupt
LI. Since disruption of LI following lesioning of the
hippocampal formation is thought to depend on the
secondary alteration of dopaminergic activity within
the nucleus accumbens, it should be sensitive to
antipsychotic treatment. Consistent with this idea,
haloperidol has been found to restore LI in
retrohippocampal-area-lesioned rats.
The present authors report the first investigation of
the effects of atypical antipsychotics on LI in
entorhinal-cortex-lesioned rats. They examined LI
using an off-baseline conditioned emotional response
paradigm in which a tone is paired with a foot-shock.
Lesions were produced by the electrolytic method.
After the recovery period, both lesioned and control
(non-lesioned) rats were administered haloperidol,
olanzapine or vehicle (saline) before both the
pre-exposure and conditioning stages of the
experiment. It was found that the deficit in LI induced
by lesioning was restored by the atypical
antipsychotic olanzapine, but not by the classical
neuroleptic haloperidol.
These findings are different from those of previous
studies showing a restoration of amphetamine-induced
disruption of LI by both typical and atypical
antipsychotics. Disruption of LI by lesions of the
entorhinal cortex may provide a way to differentiate
anatomical and/or neuropharmacological targets of
typical and atypical antipsychotic drugs. 
1. Gray JA, Joseph MH, Hemsley DR et al. The role of mesolimbic
dopaminergic and retrohippocampal afferents to the nucleus
accumbens in latent inhibition: Implications for schizophrenia.
Behav Brain Res 1995;71:19–31.
2. Coutureau E, Galani R, Majchrzak M et al. Entorhinal but not
hippocampal or subicular lesions disrupt latent inhibition.
Neurobiol Learning Memory 1999;72:143–57.
Address for reprints: E Coutureau, Laboratoire de Neurosciences
Comportementales et Cognitives, UMR 7521, CNRS/ULP, 12 rue
Goethe, Strasbourg, France.
NEUROPSYCHOLOGY
Relationship of cognitive functioning, adaptive life
skills, and negative symptom severity in poor-
outcome geriatric schizophrenia patients 
McGurk S, Moriarty PJ, Harvey PD et al.
J Neuropsychiatry Clin Neurosci 2000;12:257–64.
Cognitive impairment is a central feature of
schizophrenia. Most patients face a poor functional
outcome, including deficits in social, occupational and
self-care activities, which persist even in periods of
remission of positive symptoms of the illness. Functional
outcome in schizophrenia has been shown to be
predicted by both negative and cognitive symptoms [1]. 
Interestingly, substantial correlations have been seen
between cognitive deficits and negative symptoms,
thereby raising the possibility that extreme scorers for
negative symptoms, cognitive functioning and adaptive
functioning account for the correlation between these
variables in large samples of patients. However, it has
also been shown that although cognitive deficits and
negative symptoms correlate in their severity, there is
no longitudinal relationship between them [1]. 
The present authors thus suggested that although
positively correlated, cognitive deficits and negative
symptoms may manifest different underlying
physiological processes. To test this possibility, they
compared the relationship between cognitive
functioning and functional skills in poor-outcome
geriatric schizophrenia patients who were in the first
[n=81; a maximum total score of 18 on the Positive
and Negative Syndrome Scale (PANSS)] and the
fourth quartiles (n=127; a minimum total score of 26
on the PANSS) of negative-symptom severity based
on the normative data. 
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The results demonstrated that negative symptoms
and cognitive functioning were the strongest predictors
of functional skills in this population, regardless of the
severity of negative symptoms. Positive-symptom
severity was found to be strongly related to the
severity of impulsive behavior.
The authors suggest that, because cognitive
functioning has a significant relationship with functional
skills, the most effective way to improve the outcome
of schizophrenia is to target cognitive dysfunction.
Importantly, there appears to be considerable promise
from atypical antipsychotics, such as clozapine,
risperidone, olanzapine and quetiapine, for the
enhancement of cognitive functioning in schizophrenia.
1. Harvey PD, Howanitz E, Parrella M et al. Symptoms, cognitive
functioning, and adaptive skills in geriatric patients with lifelong
schizophrenia: A comparison across treatment sites. Am J
Psychiatry 1998;155:1080–6.
Address for reprints: S McGurk, Pilgram Psychiatric Center, Clinical
Neuroscience Treatment Unit, 998 Crooked Hill Road, Building
81/012, West Brentwood, NY 11717, USA.
Procedural learning in schizophrenia: further
consideration on the deleterious effect of neuroleptics
Bédard M-A, Schérer H, Stip E et al. 
Brain Cogn 2000;43:31–9
Procedural learning is a type of rule-based learning in
which performance facilitation occurs with practice on
task. Impaired procedural learning was reported first in
patients with parkinsonism and Huntington’s disease.
Based on these findings, the striatum was postulated
as the main neural structure underlying this type
of learning. More recently, the cerebellum and
prefrontal cortex have been proposed as important
components of the circuit subserving procedural
learning, on the basis of observations of impaired
performance in patients with cerebeller degeneration
and prefrontal damage.
Attempts to investigate procedural learning in
patients with schizophrenia have yielded conflicting
results. The authors suggest that this may be related to
the type of antipsychotic medication administered.
Conventional antipsychotics may account for procedural
learning deficits in these patients, perhaps via their
strong dopamine-blocking actions in the striatum. 
To test the above hypothesis, three groups (n=15
per group) of schizophrenic patients treated with three
different antipsychotics were compared with normal
healthy controls on two procedural-learning tasks. The
antipsychotics were chosen on the basis of their high
or low dopamine affinity, and comprised:
• haloperidol, a classical neuroleptic drug with high D2
occupancy
• clozapine, an atypical antipsychotic without
significant D2 occupancy
• risperidone, another atypical antipsychotic that
nevertheless shows a significant D2 occupancy.
The tasks for the procedural learning assessment were: 
• the Mirror Drawing Task, a visuomotor learning task
• the Tower of Toronto test, involving learning of a
problem-solving algorithm.
Patients treated with haloperidol, but not those
treated with clozapine or risperidone, showed many
fluctuations during the initial learning of the
visuomotor task. In the problem-solving task, learning
rates were slower for the haloperidol and risperidone
groups than for the control or clozapine groups. 
The authors attribute the observed fluctuations in the
haloperidol-treated patients either to a direct deleterious
effect of haloperidol on frontal lobe functions or to an
improvement in frontal lobe functions brought about by
clozapine and risperidone, but not by haloperidol. They
attribute slower learning on the Tower of Toronto test in
the haloperidol and risperidone groups to D2 receptor
blockade in the striatum by these drugs. The doses of
the various antipsychotics used in this study, however,
are not reported.
The above findings showing differential effects of
conventional and atypical antipsychotics on procedural
learning deficits in schizophrenia have important
implications for rehabilitation and reintegration of
patients, as much of the rehabilitation involves either
acquiring new skills or relearning skills that have been
lost due to the illness. Atypical antipsychotics may help
the patients to acquire skills necessary for independent
living in the community.
Address for reprints: MA Bédard, Centre de neuroscience de la
cognition, Université du Québec à Montréal, Montréal, Canada.
Neuropsychological functioning in first-episode
psychosis — evidence of specific deficits 
Riley EM, McGovern D, Mockler D et al. 
Schizophr Res 2000;43:47–55.
Patients with schizophrenia exhibit profound
neuropsychological deficits when compared with
normal healthy individuals. However, studies of
neuropsychological functioning involving chronic
schizophrenic patients do not allow one to examine
whether the cognitive impairment frequently seen in
schizophrenia reflects the disease process, long-term
neuroleptic treatment, long-term institutionalization, or
a combination or two or more of these factors. 
The authors have examined the neuropsychological
profile of a sample of 40 first-episode patients using a
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comprehensive battery including tests of executive
functions, verbal memory, non-verbal memory,
working memory, attention, psychomotor speed and
spatial ability, and compared them with a group of 22
healthy individuals.
Patients underperformed the controls on all test
variables. Significant differences were found on tasks
of executive function, including those requiring the
ability to form and initiate a strategy, to inhibit
prepotent responses, and to shift cognitive set, and
also on tasks of verbal fluency. Significant differences
were also found on verbal learning, delayed non-verbal
memory, and psychomotor speed. Impairments on
these tasks were up to two standards deviations below
the performance of controls. There was, however,
no relationship between symptomatology and
neuropsychological performance. 
Thus, it has been shown that, even at the very first
presentation of psychotic symptoms, schizophrenic
patients exhibit significant neuropsychological
abnormalities. This study represents one step forward
towards understanding schizophrenia as a ‘cognitive
disorder’. The next step perhaps should be to search
for antipsychotic (or other) treatments which would, at
least, help to preserve the current level of cognitive
functioning if not reduce the abnormalities already
present at the onset of illness in schizophrenic patients. 
Address for reprints: T Sharma, Section of Cognitive
Psychopharmacology, Division of Psychological Medicine, Institute of
Psychiatry, De Crespigny Park, Denmark Hill, London SE5 8AF, UK.
Neuropsychological and conditioned blocking
performance in patients with schizophrenia:
Assessment of the contribution of neuroleptic dose,
serum levels and dopamine D2-receptor occupancy
Oades RD, Rao ML, Bender S et al.
Behav Pharmacol 2000;11:317–30.
Conventional drugs used to treat patients with
schizophrenia primarily act on dopamine D2 receptors.
Patients with schizophrenia often exhibit deficits in tasks
requiring selective attention (e.g. latent inhibition and
conditioned blocking) and standard neuropsychological
tests of frontal lobe functioning (e.g. verbal fluency and
card sorting). Such deficits are also associated with
symptoms of the illness — for example, impaired latent
inhibition is seen in patients with positive psychotic
symptoms. Importantly, performance on some of these
tasks is also known to be affected by manipulations of
dopamine activity. The extent to which performance
deficits in schizophrenic patients are due to
antidopaminergic medication is largely unexplored.
The authors examined the putative influence of the
dose of antipsychotic medication, the antipsychotic
serum concentration of D2-blocking activity and the
approximated central D2-receptor occupancy on the
conditioned blocking effect (CBE) — retardation of
learning about the consequences of a stimulus-
component (B in AB) when these consequences are
already becoming associated with another component
(A in AB) — and performance on a range of
neuropsychological tasks in 108 patients with
schizophrenia. The control group comprised 62
healthy subjects.
The antipsychotic serum concentration of
D2-blocking activity and the approximated central
D2-receptor occupancy were higher in paranoid
compared with non-paranoid patients, and in female
compared with male patients; this effect was unrelated
to symptom severity. Controlling for D2-receptor
occupancy abolished the difference between paranoid
(high CBE) and non-paranoid (low CBE) patients.
Performance of some other tasks also showed a
functional relationship with D2 activity. High estimates
of central D2 occupancy were associated with impaired
verbal fluency but improved recall of stories, especially
in paranoid patients. 
This is the first study to have examined the putative
role of dopamine activity in left frontal (e.g. verbal
fluency) and temporal lobe (e.g. story recall) functions
in patients with schizophrenia. Although the study was
limited by the availability of central D2-occupancy data
for only five of the commonly prescribed antipsychotics
(haloperidol, risperidone, flupenthixol, clozapine and
olanzapine), and relatively crude estimations of
occupancy data, it is valuable in providing working
hypotheses for the role of D2-related activity in
attention and recall.
Address for reprints: RD Oades, University Clinic for Child and
Adolescent Psychiatry and Psychotherapy, Virchowstrasse 174,
D-45147 Essen, Germany.
Is anhedonia a specific dimension in chronic
schizophrenia?
Loas G, Noisette C, Legrand A et al.
Schizophr Bull 2000;26:495–506.
Anhedonia, the reduced ability to experience pleasure, is
a common feature of depression. It is also considered to
be an early symptom and a stable trait in schizophrenia.
However, it has been shown that depressive-like
symptoms in schizophrenia are related to the use of
neuroleptics and that a strong link exists between
neuroleptic use and anhedonia. Some researchers have
suggested that anhedonia is a persistent negative
symptom in schizophrenia, while others have found it to
be independent of depressive symptoms.The present
authors used factor analysis methods to clarify the
relationship among anhedonia, depression, and
schizophrenic symptoms in chronic schizophrenia. 
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The study group comprised 150 subjects (86 males
and 64 females) who met research diagnostic criteria
for definite chronic schizophrenia. They completed two
self-rating scales: the French version of the abridged
form of the Beck Depression Inventory, and the
Fawcett Clark Physical Pleasure Capacity Scale. The
choice of the Physical Capacity Scale, as opposed to
the Social Anhedonia Scale, was made as it represents
a relatively pure form of hedonic capacity and is less
influenced by psychological factors, such as anxiety.
Schizophrenic symptoms were rated using the Positive
and Negative Syndrome Scale. 
The authors subjected the data to rigorous statistical
techniques and, on the basis of their findings,
concluded that anhedonia is not a negative symptom
that co-varies with other classical negative symptoms.
Their results also supported the view that anhedonia is
separate and distinct from depression in schizophrenia.
The relationship between antiparkinsonism and
anhedonia, however, was not examined
The findings of this study led the authors to
propose, firstly, that anhedonia may be the main
characteristic of a particular syndrome in chronic
schizophrenia, and, secondly, that there may be a
subgroup of chronic schizophrenia patients
characterized by severe anhedonia. 
Address for reprints: G Laos, Secteur Hospitalo-Universitaire, Hôpital
Pinel, 80044 Amiens cedex 01, France.
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A positron emission tomography study of quetiapine
in schizophrenia: A preliminary finding of an
antipsychotic effect with only transiently high
dopamine D2 receptor occupancy
Kapur S, Zipursky R, Jones C et al.
Arch Gen Psychiatry 2000;57:553–9. 
Quetiapine is an atypical antipsychotic with evidence of
efficacy in schizophrenia at doses of ≥300 mg per day.
It is associated with an incidence of extrapyramidal side
effects and prolactin level elevation similar to that of
placebo. This study was designed to investigate its in
vivo effects on the D2 and 5-HT2 receptor systems,
using positron emission tomography (PET) with two
radioligands, [11C]-raclopride and [18F]-setoperone.
Twelve patients with schizophrenia were randomly
assigned to receive one of four doses of quetiapine:
150, 300, 450 or 600 mg per day. After 3 weeks of
treatment, they underwent PET imaging 12 h after the
last dose. After the PET scan, the patients reverted to
flexible dosing (150–600 mg/day) and were evaluated
with structured ratings for another 8 weeks. A further
two patients were scanned 2–3 h after the last dose to
see the acute effects of quetiapine.
At 12 h after the last dose, D2 occupancy ranged
between 0 and 27%. Despite these low levels of D2
receptor occupancy, treatment with quetiapine was
associated with significant improvement on clinical
scales, significant effects on positive symptoms, and a
trend towards a significant effect on general symptoms.
Furthermore, there were low levels of extrapyramidal
side effects. There was also a general reduction in
prolactin levels (the basal levels probably being increased
because of the previous use of typical antipsychotics).
Of particular interest were the two patients who
received scans 2–3 h after the last dose. In these
patients, D2 occupancy was 58% and 64%, respectively.
However, when these patients were rescanned after
9 and 24 h, respectively, occupancy had declined to
20% and 0%, leading the authors to suggest that
quetiapine has only a transient effect on D2 receptors.
The effect on 5-HT2 receptors was more characteristic,
with a dose-dependent receptor occupancy averaging
20% at the lowest dose and 78% at the highest dose.
Drawbacks of this study include the lack of any
control for non-pharmacological factors in treatment.
In addition, only striatal D2 receptor occupancy was
measured, rather than other extrastriatal regions,
which are thought to be responsible for the
antipsychotic effect. Nevertheless, this study does
suggest very low D2 occupancy 12 h after the last dose
of quetiapine and yet clear antipsychotic efficacy. The
authors suggest that transient D2 occupancy may be
sufficient to induce an antipsychotic response. This is a
very interesting hypothesis, and one that is likely now
to be taken forward in further studies.
Address for reprints: S Kapur, PET Centre, The Clarke Institute of
Psychiatry, 250 College Street, Toronto, Ont. M5T 1R8, Canada.
Cognitive performance in relation to MRI temporal
lobe volume in schizophrenic patients and healthy
control subjects
Krabbendam L, Derix MMA, Honig A et al.
J Neuropsychiatry Clin Neurosci 2000;12:251–6.
The aim of this study was to see if specific cognitive
deficits are present in schizophrenia and if these are
related to specific areas of brain atrophy. The study
group comprised 27 patients with schizophrenia,
diagnosed according to DSM-IV criteria and verified
using the Composite International Diagnostic Interview,
and 19 healthy control subjects. All patients were
medicated at the time. Although well matched in other
variables, the schizophrenic patients had a significantly
lower IQ than the controls. A neuropsychological test
battery was performed, with particular emphasis on
tasks involving speed of cognitive processing. Structural
magnetic resonance images were acquired, and a
region-of-interest analysis was applied, involving
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manual outline of the amygdala, hippocampus,
parahippocampal gyrus and temporal lobe.
There was no difference in the volume of the brain
regions between patients and controls. However, the
speed of performance on the Stroop Color-Word Test
(SCWT) and the Concept Shifting Test was significantly
lower in patients than controls. This difference tended
to increase as the tasks became more difficult. In the
patient group, the volume of the left parahippocampal
gyrus was inversely correlated with performance on
the third part of the SCWT. This was present across all
patients and not just limited to those with the lowest
IQs. Performance on the other tasks did not correlate
with the volume of any of the brain regions
investigated. In the control group, no significant
correlations were found between brain structure
volume and cognitive performance.
In their discussion, the authors note that this
association between parahippocampal gyrus volume
and cognitive performance has been previously
reported. They suggest that this finding is consistent
with the theory of a disturbance in the circuitry
connecting dorsolateral prefrontal, temporal and limbic
areas, a network required for the active maintenance
of task-relevant information. However, they accept
that this was a small sample, and that patients were
taking antipsychotic medication, and suggest the need
for the finding to be replicated.
Address for reprints: L Krabbendam, Department of Psychiatry and
Neuropsychology, Psychomedical Center Vijverdal, PO Box 88, 6200
AB Maastricht, The Netherlands.
Reduced anterior cingulate gyrus volume correlates
with executive dysfunction in men with first-episode
schizophrenia
Szeszko PR, Bilder RM, Lencz T et al.
Schizophr Res 2000;43:97–108.
The authors introduce this study by noting that,
although there is a large degree of evidence implicating
frontal lobe structural and functional abnormalities in
schizophrenia, the relationship between them is less
clear. They suggest that this may be because previous
studies have failed to take into account the
heterogeneous nature of the frontal lobe, and have
especially failed to take into account subregions within
it. Particular attention is drawn to the presence of
archicortical and paleocortical regions, which have
different developmental origins and possibly different
functions. The authors hypothesized that the volumes
of two dorsal archicortical subregions, but not a ventral
paleocortical subregion, would be significantly and
selectively correlated with executive and motor
dysfunction in patients with schizophrenia, as previously
reported for the anterior hippocampal region.
In order to answer this question, they performed
structural MRI on 35 patients (20 males, 15 females)
with schizophrenia or schizoaffective disorder. They
were all first-episode patients with less than 12 weeks’
(lifetime) use of antipsychotics. Frontal subregions were
delineated using a manually defined method aided by
computer. All patients also completed a comprehensive
neuropsychological test battery when clinically stable.
Results suggested that among men, but not among
women, reduced anterior cingulate gyrus volume was
significantly correlated with worse executive function.
No other correlations between frontal lobe subregions
and neuropsychological domains were significant.
Among men, anterior cingulate gyrus volume was
significantly more strongly correlated with executive
functioning than with memory, language, attention,
visuospatial and general intellectual functioning.
The authors interpret their results as showing a
specific association between reduced anterior
cingulate gyrus volume and executive functioning in
men. They classify the association as specific because
there was no association between the anterior
cingulate and any other aspect of neuropsychological
functioning measured. They suggest that this specific
subregion approach may be a more fruitful avenue for
the future than trying to correlate the whole frontal
lobe with neuropsychological function. Furthermore,
they discuss the sex differences, noting that their
findings may be indicative of differences in the pattern
of frontal lobe structure–function relations in
schizophrenia between men and women. Although
the weaknesses of this study include the low subject
numbers, the strengths include the use of first-episode
patients with short-term use of medication and
comprehensive assessment procedures.
Address for reprints: PR Szeszko, Department of Psychiatry Research,
Hillside Hospital, North Shore-Long Island Jewish Health System,
75-59 263rd Street, Glen Oaks, NY 110044, USA.
Neural correlates of memory organization deficits in
schizophrenia: A single photon emission computed
tomography study with 99mTc-ethyl-cysteinate dimer
during a verbal learning task
Nohara S, Suzuki M, Kurachi M et al.
Schizophr Res 2000;42:209–22.
This study set out to investigate frontal lobe function in
schizophrenia. The method used was measurement of
regional cerebral blood flow (rCBF), using single
photon emission computed tomography (SPECT). The
study group comprised 10 male patients with
schizophrenia and nine healthy male volunteers. All
patients were diagnosed using ICD-10 criteria and all
were taking antipsychotic medication with or without
anticholinergic drugs. Subjects were asked to
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undertake a verbal learning task. This involved learning
three lists of 20 words, which differed in degree of
semantic organization. Verbal repetition was used as a
control task. Analysis was performed using a manual
Region of Interest comparison based on co-registered
magnetic resonance imaging templates.
For the verbal learning task, schizophrenics
performed more poorly than controls, regardless of
whether the word list was random or given semantic
meaning. In the control subjects, rCBF during the
verbal learning task was significantly higher than the
baseline during the verbal repetition task in the left
inferior frontal and left anterior cingulate regions. In
the schizophrenic patients, however, there was no
significant activation by the verbal learning task in any
region. Compared with controls, patients had
significantly reduced rCBF during the verbal learning
task, with statistical significance in the bilateral inferior
frontal regions and a tendency towards significance in
the left anterior cingulate, left superior frontal, and
bilateral middle frontal regions. In the controls but not
in the patients, activation in the left inferior frontal
region was significantly positively correlated with the
categorical clustering in the task.
The authors suggest that their findings provide
evidence that schizophrenic patients have poorer
memory function, specifically in the use of semantic
organizational strategies, and that this is associated
with a failure to activate frontal regions. They note the
problems in understanding whether the failure of
activation is due to the poorer performance of the task
or to a specific dysfunction in this brain area. This
point still requires elucidation. Other confounding
influences on the study include the use of medicated
patients and the fact that all were male. There was
also no attempt made to link any of the findings to
clinical processes or symptoms.
Address for reprints: S Nohara, Department of Neuropsychiatry,
Toyama Medical and Pharmaceutical University, 2630 Sugitani,
Toyama 930-0194, Japan.
A five-year longitudinal study of the regional cerebral
metabolic changes of a schizophrenic patient from the
first episode using Tc-99m HMPAO SPECT
Chen RYL, Chen E, Ho WY.
Eur Arch Psychiatry Clin Neurosci 2000;250:69–72.
An area of continuing interest in schizophrenia research
is the application of neuroimaging techniques to
elucidate the neural correlates of clinical and cognitive
abnormalities. There have been several previous
attempts employing between-subjects designs to
examine the relationship between symptoms,
treatment response and regional brain activity.
Longitudinal within-subjects studies are now required
to examine whether abnormal patterns of regional
cortical activity seen in schizophrenic patients represent
transient symptom/treatment-related changes or
whether they are persistent features of the illness.
The authors present a naturalistic study of the
relationship between cerebral metabolic activity, clinical
symptoms and treatment response in a young female
schizophrenic patient for 5 years from the onset of her
illness (aged 19 at the time of the illness onset). Serial
technetium-99m hexamethyl-propyleneamine oxime
(HMPAO) brain single-photon emission computerized
tomography (SPECT) was used to measure regional
cerebral metabolism. Her neurocognitive abilities were
assessed with the Cambridge Neurological Inventory,
Wisconsin Card Sorting Test, Wechsler Adult
Intelligence Scale (WAIS-R) verbal subscales, semantic
verbal fluency test, and logical memory in Weschler
Memory Scale. SPECT scans were taken on six
occasions over the course of her illness.
The first scan was performed 6 months after the
onset of her illness (first-episode) and 1 week after she
had started on haloperidol but still had psychotic
symptoms. She achieved full clinical remission after 2
weeks on haloperidol. The second and third scans were
performed 10 and 40 months after the onset,
respectively, during remission, while she was on
maintenance medication with sulpiride (100 mg/day).
The medication had been changed from haloperidol to
sulpiride because of the side effects. The fourth scan
was performed 44 weeks after the onset, during the
second psychotic episode; this episode was attributed to
poor drug compliance. She responded well to sulpiride
(400 mg/day), but 6 months later relapsed again. The
fifth scan was obtained during this (third) episode, 56
weeks after the onset. This time she also had negative
symptoms and cognitive impairments, and failed to
respond to conventional antipsychotics (trifluoperazine
up to 53 mg/day and haloperidol up to 55 mg/day for
8 weeks each). However, she responded well to
clozapine (300 mg/day). Her symptoms subsided
completely and cognitive functioning normalized
2 months after treatment. The sixth scan was acquired
at 56 weeks, during clinical remission.
Left anterior temporal lobe under-activity was seen in
the first scan, but this had returned to normal levels in
the second scan, i.e. during remission. Left prefrontal
under-activity was also noted in both the first and
second scans. In the third scan, left anterior temporal
lobe under-activity emerged again, despite clinical
remission. The fourth scan, during the second psychotic
episode, showed under-activity in the left temporal
lobe. There was under-activity of both prefrontal lobes
and of the left anterior temporal lobe in the fifth scan.
However, in the sixth scan, the right prefrontal activity
— but not the left — had returned to normal. 
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Although limited by a single-case design, this study
presents valuable data on regional cerebral metabolic
changes during remission, relapse and development of
treatment resistance in schizophrenia and provides
some insight into this illness as a ‘brain disease’. Its
findings suggest that clozapine treatment may improve
metabolic activity in the frontal lobes. It remains to be
seen whether such effects will also be observed with
clozapine treatment in patients with relatively longer
duration of illness.
Address for reprints: RYL Chen, Department of Psychiatry, Room
219, J2 Block, Queen Mary Hospital, Pokfulam, Hong Kong.
ETIOLOGICAL FACTORS
Obstetric complications and schizophrenia: Two case-
control studies based on structured obstetric records
Kendell RE, McInneny K, Juszczak E et al.
Br J Psychiatry 2000;176:516–22.
Obstetric complications and affective psychoses:
Two case-control studies based on structured 
obstetric records
Bain M, Juszczak E, McInneny K et al.
Br J Psychiatry 2000;176:523–6.
Labour and delivery complications and schizophrenia:
Case-control study using contemporaneous labour
ward records
Byrne M, Browne R, Mulryan N et al.
Br J Psychiatry 2000;176:531–6.
The broad principle of both genetic and non-genetic
factors contributing to the etiology of schizophrenia is
well established. Efforts to identify specific such factors
have met with more frustration than success. This is
particularly true regarding the role of perinatal and
obstetric complications (PBCs) in the development of
schizophrenia, where results so far have been either
conflicting or inconclusive. The studies on PBCs
reviewed here, tried to address three key methodological
shortcomings of most previous studies, namely:
• sample selection biases
• validity of PBC data
• specificity of possible findings to schizophrenia
compared with other severe psychiatric disorders
such as affective psychoses. 
All three studies used large population-based
registers from either Scotland (first two) or Ireland
(third) to identify cases of schizophrenia and control
subjects. Clinical diagnoses were provided from
centralized registers, and information on PBCs was
obtained from the actual obstetric records for all
subjects. Controls were tightly matched to cases on
age, gender, maternal age at the time of delivery,
parity and socioeconomic status. Patients and controls
were compared on the total number as well as on
individual PBCs. The unanimous finding of all three
studies was the lack of difference in the total number
of PBCs between controls and patients with
schizophrenia or affective psychoses. When individual
PBCs were examined, the results were less consistent,
with one type of PBC being more common in patients
in one cohort but not in another. With the possible
exception of the finding of excess emergency
caesarian sections reported in two of the studies, other
positive findings regarding individual PBCs were
probably spurious. 
It would appear, based on the above, that the
role of PBCs in the pathogenesis of schizophrenia is
rather limited. As none of the specific PBCs were
prevalent, it would be difficult to formulate any
arguments as to any pathophysiological link between
PBCs and schizophrenia.
Addresses for reprints: RE Kendell, 3 West Castle Road, Edinburgh
EH10 5AT, UK. RE Kendell, 3 West Castle Road, Edinburgh EH10
5AT, UK. E O’Callaghan, Cluain Mhuire Community Psychiatric
Service, Newtownpark Avenue, Clackrock, Co. Dublin, Ireland.
Prepulse inhibition of the startle response in men with
schizophrenia: Effects of age of onset of illness,
symptoms, and medication
Kumari V, Soni W, Mathew VM et al.
Arch Gen Psychiatry 2000;57:609–14.
Prepulse inhibition (PPI) is defined as a reduction in
response to a startling stimulus when preceded by a
non-startling subthreshold stimulus. It is used an index
of attention and information processing. Previous basic
and clinical research has shown PPI to be abnormal in
schizophrenia, but this finding is susceptible to the
effects of medication and clinical features such as the
severity and age of onset of illness.
These authors examined the effects of the age of
onset, current positive and negative symptoms, and the
type of medication on PPI in a group of 38 male patients
(aged 20–59 years) with a diagnosis of schizophrenia or
schizoaffective disorder. Twenty healthy males (aged
20–50 years) served as controls. Ten patients had illness
onset in adolescence (aged <20 years) and 28 had
adult-onset illness. Nine patients were on typical
antipsychotics and 29 were on atypical antipsychotics.
Female patients were not tested, given the previous
findings of gender and hormonal effects on PPI.
Acoustic stimuli were presented to subjects binaurally
and electromyographic activity was recorded for 250 ms
post-stimulus. The PPI response was measured at
prepulse-to-pulse intervals of 30, 60 and 120 ms.
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A significant positive relationship was found
between the age of illness onset and PPI at 60 and 120
ms intervals. PPI was significantly reduced in the early-
onset group but not in the adult-onset group,
compared with controls. No significant relationships
were found between PPI and symptoms, age at
testing, psychopathology, duration of illness, number
of episodes, and medication dose. There was some
indication that treatment with typical antipsychotics
reduced PPI compared with controls, but only at short
prepulse trials. The overall pattern, however, was of no
difference in PPI between patients on typical or
atypical antipsychotics and controls.
The authors suggest that their finding of a lack of PPI
normalization in males with early-onset schizophrenia,
even when treated with atypical antipsychotics, is
consistent with the reported poor outcome and
treatment response in this group of patients. As PPI is an
objective and simple experimental tool that could be
used to examine heterogeneity in illness and
responsiveness to antipsychotic medication in
schizophrenia, this finding is potentially very interesting.
However, it is worth noting that there was no evidence
of poorer medication response in this group of early-
onset cases, as their symptom scores were no different
from those of the adult-onset cases. Furthermore, the
study included a sample of only 10 early-onset patients,
who were treated with a variety of antipsychotics for
variable periods. As the authors themselves
acknowledge, further longitudinal studies with
concurrent structural and functional brain measurements
in a larger sample are required to examine closely the
relationship between PPI and age of onset.
Address for reprints: T Sharma, Section of Cognitive
Psychopharmacology, Division of Psychological Medicine, Institute of
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Childhood cognitive functioning in schizophrenia
patients and their unaffected siblings: A prospective
cohort study
Cannon TD, Bearden CE, Hollister JM et al.
Schizophr Bull 2000;26:379–93.
Neurodevelopmental disturbances are thought to
contribute to the etiology of at least some cases of
schizophrenia. However, it is not known what the
etiologic correlates of these disturbances are, or what
proportion of the schizophrenia population is
characterized by them. Prospective study of cognitive
functioning in people who develop schizophrenia
provides one way to address these issues.
Longitudinal high-risk studies have provided
consistent evidence that the children of patients with
schizophrenia exhibit poorer neuropsychological
functioning than the children of healthy individuals.
These findings indicate that early signs of brain
dysfunctioning in pre-schizophrenic individuals may at
least to some extent be mediated by genetic
predisposition to develop the illness. However, limited
information is currently available to determine the
degree to which
early cognitive dysfunctioning predicts schizophrenia
in such populations. It is also unclear whether high-risk
findings apply to the total population of schizophrenic
subjects, or whether they are relevant to only the
subgroup of patients with a parent diagnosed with
schizophrenia.The present authors used a prospective
cohort design to examine:
• the degree to which cognitive dysfunctioning in
childhood is predictive of schizophrenia in later life
• whether unaffected siblings of those later diagnosed
with schizophrenia also display similar deficits
• the time course of these abnormalities
• whether there is a relationship between fetal
hypoxia/other obstetric complications and cognitive
performance.
The study group comprised 72 patients with
schizophrenia or schizoaffective disorder, 63 of their
siblings not diagnosed with schizophrenia, and 7971
control subjects, all selected from a birth cohort whose
members had been cognitively assessed at 4 and 7
years of age.
Both the patients and their unaffected siblings
performed significantly worse than the non-
psychiatric controls on verbal and non-verbal
cognitive tests at 4 and 7 years of age; patients did
not differ significantly from siblings. There was no
relationship between obstetric complications and
cognitive performance. While it is possible that the
sibling group contained a certain percentage of
people (about 5%) who may be diagnosed with
schizophrenia in their lifetime, it is unlikely to explain
the deficits observed. 
The pre-schizophrenic subjects did not show intra-
individual decline in cognitive performance. As
suggested by the authors, this may be due to the
limited ability to detect such decline in children as
compared with adults, since the former group
undergoes both qualitative and quantitative changes
with age. Given that by early adulthood most
schizophrenic patients perform more poorly on
cognitive tests than their unaffected siblings, it is likely
that pre-schizophrenic subjects increasingly diverge
from the functioning levels expected in their own
families with age. 
Address for reprints: Professor TD Cannon, University of California,
Department of Psychology, 1285 Franz Hall, Box 951563, Los
Angeles, CA 90095-1563, USA.
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The relationship of prenatal and perinatal
complications to cognitive functioning at age 7 in the
New England cohorts of the National Collaborative
Perinatal Project
Seidman LJ, Buka SL, Goldstein JM et al.
Schizophr Bull 2000;26:309–21.
Elevated rates of prenatal and perinatal complications
(PPCs) have been associated with the development of
schizophrenia. A variety of other factors — such as a
positive family history for schizophrenia, poor
school/childhood adjustment, cognitive dysfunctioning,
and poor motor coordination — have also been found
to be related to development of this illness. However,
not much is currently known about the relationship of
these risk factors to each other and whether they reflect
common or different pathways.
The present authors examined the relationship
between PPCs and cognitive functioning in a large
epidemiological study of pregnancy, birth, and
development: the National Collaborative Perinatal
Project (NCPP). Thirteen standardized measures of
cognitive abilities were obtained on 11 889 children at
approximately age 7. The authors performed principal
component analysis using the 13 cognitive variables to
create three neuropsychological measures: academic
achievement skills, verbal-conceptual abilities, and
perceptual motor abilities. They then measured the
relationship between these factors and three measures
of PPCs: low birth weight, presumed hypoxic insults,
and conditions reflecting possible chronic hypoxia. 
All three measures of PPCs were significantly
associated with lower cognitive performance for each
of the three factors, after controlling for possible
confounding variables, such as socioeconomic status,
race, mother’s age at birth, age of child at assessment,
and NCPP site. Low birth weight had the strongest
association with cognitive performance, followed by
presumed hypoxic insults. Co-occurrence of the three
indicators of PPCs was relatively low.  
Although the findings suggest that PPCs are
associated with a relatively generalized deficit, it is
possible — as noted by the authors themselves — that
patterns of association between these PPCs and
cognitive functioning may change with development.
Such a model has previously been proposed by
Weinberger [1], to account for frontal lobe deficits in
people with schizophrenia who previously were
relatively symptom-free.
The authors intend to investigate in future studies
whether the association observed between PPCs and
poor cognitive functioning is also true in offspring of
subjects with schizophrenia or affective psychoses, to
test the specificity of certain PPCs on cognitive
functioning in schizophrenia. It is important to note that
a previous report from the NCCP [2] described different
effects of PPCs on intellectual functioning in children of
schizophrenic patients and unselected controls.
1. Weinberger DR. Implications of normal brain development for the
pathogenesis of schizophrenia. Arch Gen Psychiatry
1987;44:660–9.
2. Reider RO, Broman SH, Rosenthal D. The offspring of
schizophrenics: II. Perinatal factors and IQ. Arch Gen Psychiatry
1977;34:789–99.
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Service use and costs of people with dual diagnosis in
South London
McCrone P, Menezes PR, Johnson S et al.
Acta Psychiatr Scand 2000;101:464–72.
The significant level of comorbidity between
psychosis and substance abuse — so-called dual
diagnosis — has led to the setting up of special
services to deal with the problem. There is a general
feeling that some psychiatric services may be more
heavily used by such dual-diagnosis patients, whereas
others may be underused. The authors prospectively
studied a group of dual-diagnosis patients and a
comparison group of patients with psychosis but no
substance abuse over 6 months to measure service
usage and associated costs.
The study was carried out at the Maudsley Hospital in
South London. Overall, 101 patients with psychosis
were interviewed, 27 (29%) of whom were considered
to be dual diagnosis. Of these, eight (9%) had an
alcohol problem, 11 (12%) had a drug-related problem
and eight (9%) had both. Significantly higher
proportions of the dual-diagnosis patients used inpatient
care, the emergency clinic and community psychiatric
nurses. Furthermore, the intensity with which dual-
diagnosis patients used inpatient care was also
significantly higher. The overall costs of service use were
calculated using a model that included not just direct
health service costs but also more indirect social service
costs. The mean cost per patient was just over UK£1000
(US$1600) higher in the dual-diagnosis group.
In discussing the implications of these results, the
authors note that the patients with dual diagnosis were
on average younger and functioning at a lower level
than those in the comparison group. This needs to be
taken into account when targeting services towards
this group. The authors suggest that it is important to
see whether specific training of staff and development
of dual-diagnosis teams can reduce costs and improve
the outcome in dual diagnosis. They suggest that
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prospective studies, including an economic component,
should be undertaken to evaluate this.
Address for reprints: P McCrone, Section of Community Psychiatry,
Institute of Psychiatry, De Crespigny Park, London SE5 8AF, UK.
Maternal recall of pregnancy history: Accuracy and
bias in schizophrenia research
Buka SL, Goldstein JM, Seidman LJ et al.
Schizophr Bull 2000;26:335–50.
Perinatal and obstetric complications (referred to as
pregnancy and birth complications in the paper (PBCs))
have attracted research interest because of their
putative contribution to the causation of schizophrenia.
One methodological problem complicating the
interpretation of findings in this field is that most
studies are based mainly on retrospective maternal
recall, which may not be entirely accurate. In this
paper, the authors examined whether there is indeed
recall biases in reporting PBCs by mothers of psychotic
patients compared with mothers of healthy controls.
The subjects were selected from the Providence and
Boston cohorts of the National Collaborative Perinatal
Project. Members with psychotic illness were identified
through interviews and/or record search, and were
screened to confirm their diagnoses. Thirty-nine of
these subjects were then randomly selected and
matched for sociodemographic variables and history of
obstetric complications to a control sample of equal
size. The mothers of these subjects were interviewed
over the phone using the Pregnancy History
Instrument, a composite of PBC scales identified in the
literature. This information was then compared with
the actual obstetric records held on the subjects. 
Although the total number of errors was highly
comparable for the patient and control groups, the
types of errors committed differed. Mothers of controls
were equally likely to report PBCs not mentioned in
their obstetric records (error of commission) as to miss
out PBCs (error of omission). However, in general, the
mean number of complications based on maternal
report in controls was not different to that based on
obstetric records. In contrast, mothers of offspring with
psychosis reported on average one less PBC than
indicated in the charts. In addition, they committed
more than twice as many errors of omission than errors
of commission, a difference statistically significant for
pregnancy complications (p=0.01) but not for total
complications (p=0.12).
These findings are at odds with those of the other
two published studies on the accuracy of maternal
recall of PBCs in schizophrenia. The first study, from
O’Callaghan et al [1], suggested that maternal recall
was very accurate, while the more recent study, by
Cantor-Graae et al [2], found a significantly higher rate
of errors of commission in mothers of schizophrenic
patients, particularly those without a family history of
the disorder. This would suggest that studies on the
accuracy of maternal recall of PBCs in schizophrenia
are themselves methodologically complex and
therefore unlikely to contribute to our understanding
of the role of PBCs in schizophrenia. Given that large
cohort studies using information from
contemporaneous records (see below) found a rather
limited role for PBCs in schizophrenia, one wonders
whether it is worth exploring this field further. 
1. O’Callaghan E, Larkin C, Waddington JL. Obstetric complications
in schizophrenia and the validity of maternal recall. Psychol Med
1990;20:89–94.
2. Cantor-Graae E, Cardenal S, Ismail B et al. Recall of obstetric
events by mothers of schizophrenic patients. Psychol Med
1998;28:1239–43.
Address for reprints: SL Buka, Harvard School of Public Health,
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Objective and subjective extrapyramidal side effects
in schizophrenia: Their relationships with negative
and depressive symptoms
Dollfus S, Ribeyre JM, Petit M.
Psychopathology 2000;33:125–30.
The interrelationship between drug-induced
extrapyramidal symptoms (EPS), negative symptoms
and depressive symptoms of schizophrenia has long
been the subject of debate. Some authors have
attempted to isolate depressive and negative
symptoms with the least overlap of EPS. In contrast,
no study has tried to isolate EPS independent of
depressive and negative symptoms. Therefore, the aim
of this study was to identify EPS unrelated to
depression and negative symptoms. The authors
hypothesized that subjective EPS are less interrelated
to negative and depressive symptoms than objective
EPS. This was based on the theory that objective EPS
are more subject to observer bias and to
misclassification because of coexisting depressive and
negative features.
The study group comprised 91 patients with
schizophrenia as diagnosed by at least one of four
diagnostic criteria. Fifty-three patients were in an acute
phase and 38 were stable. All patients were on
antipsychotics. Patients were evaluated using the Scale
for the Assessment of Negative Symptoms (SANS), the
Montgomery and Asberg Depression Rating Scale and
the Extrapyramidal Symptom Rating Scale.
Objective EPS scores were significantly correlated to
SANS scores (r=0.51; p<0.001) and to depressive
scores (r=0.26; p<0.01). In contrast, no significant
correlations were observed between subjective EPS
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scores and depressive or negative scores. The
correlation between objective EPS scores and
depressive scores disappeared when the negative-
symptom correlation was taken into account. These
results held across all subgroups of patients (i.e. the
acute vs. stable subgroups, the deficit vs. non-deficit
subgroups, and the diagnostic subgroups).
On the basis of their findings, the authors suggest
that clinicians should pay more attention to subjective
complaints of EPS since these are less likely to be
confounded by features of the disease, in particular
negative symptoms.
Address for reprints: S Dollfus, Centre Esquirol, Centre Hospitalier
Universitaire, F-14000 Caen, France.
Finnish adoptive family study: Sample selection and
adoptee DSM-III-R diagnoses
Tienari P, Wynne LC, Moring J et al.
Acta Psychiatr Scand 2000;101:433–43.
This is the first article in a series from the Finnish
Adoptive Family Study of Schizophrenia reporting the
application of DSM-III-R diagnostic criteria to both
adopting-away mothers and adoptees followed-up into
adulthood. This approach, first introduced in
schizophrenia research by Heston [1] and known as the
adoptees’ study method, is useful in evaluating the roles
of both genetic and environmental factors in illness and
its development. It involves the study of biological and
rearing parents separately and thus allows one to
disengage genetic and environmental factors
contributing to schizophrenia. The authors compared: 
• Finnish hospital diagnoses of schizophrenic/paranoid
psychosis in a nationwide survey of adopting-away
women with DSM-III-R diagnoses for these mothers
(index mothers)
• DSM-III-R diagnoses of their offspring (index
adoptees) with adopted-away offspring of
epidemiologically unscreened control mothers (of
which 3.5 % had diagnoses of schizophrenia
spectrum disorders and 1% had affective
psychoses). 
The primary sampling diagnoses of index mothers
were confirmed using DSM-III-R criteria. The lifetime
prevalence of typical schizophrenia in 164 index
adoptees was significantly greater (6.7%; age-
corrected morbid risk 8.1%) than that observed for
197 control adoptees (2%; age-corrected morbid risk
2.3%). This difference further increased when the
diagnoses of schizoaffective disorder, schizopheniform
disorder, schizotypal disorder and affective psychoses
were added. There was no evidence for an increased
prevalence of other diagnoses, including alcoholism,
non-psychotic depression or anxiety disorders, in
index adoptees.
Thus, the findings confirmed the genetic liability
both for ‘typical’, narrowly defined DSM-III-R
schizophrenia and for a schizophrenia spectrum that
includes non-affective psychoses and schizotypal
personality disorder. No evidence was found for a link
between mental disorders in general and the genetic
liability to schizophrenia. 
The authors, to their credit, have considered the
possibility that schizophrenic illness of women who
become mothers may be less genetically ‘loaded’ than
for non-mother schizophrenic women, as indicated by
previous findings showing relatively later onset of
illness in mothers than non-mothers. 
The data addressing the issue of environmental
protective and predisposing factors with the adoptive
rearing families in this sample are to appear in
forthcoming reports from this research group.
1. Heston L. Psychiatric disorders in foster home reared children of
schizophrenic mothers. Br J Psychiatry 1966;112:819–25.
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Randomized, placebo-controlled pilot study of
divalproex sodium in the treatment of acute
exacerbations of chronic schizophrenia
Wassef AA, Dott SG, Harris A et al.
J Clin Psychopharmacol 2000;20:357–61. 
One of the neurochemical theories of schizophrenia
involves the γ-aminobutyric acid (GABA) system. It is
generally thought that GABAergic drugs downregulate
dopamine systems. Consequently, GABA agonists may
have a potential role in the treatment of
schizophrenia. The authors present a brief report of a
prospective, double-blind, placebo-controlled pilot
study using divalproex as an adjunctive treatment in
acute schizophrenia.
The study group comprised 12 patients hospitalized
for acute exacerbations of chronic schizophrenia, as
diagnosed by the Research Diagnostic Criteria.
Antipsychotic treatment was commenced with a fixed-
dose regimen of haloperidol 10 mg per day for 3 days
and then 15 mg per day for 18 days. Patients were
randomized to receive either divalproex (dose adjusted
to achieve a target serum concentration between 75
and 100 µg/ml) or placebo, on days 1–14. Between
days 15 and 21, patients who had been assigned to
receive divalproex crossed over to placebo, whereas
those receiving placebo continued on placebo. The
usual outcome variables were used, including the
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Clinical Global Impression Scale (CGI), the Brief
Psychiatric Rating Scale (BPRS) and the Schedule for
Assessment of negative Symptoms (SANS).
At baseline, there were no statistically significant
differences on the CGI, BPRS and SANS scores between
the two treatment groups. On day 21, however, the
divalproex-augmented group had significantly better
CGI and SANS scores than the placebo group, with a
trend in the same direction on the BPRS.
The authors conclude that the addition of
divalproex to standard antipsychotic treatment may
prove effective in relieving both the positive and
negative symptoms of acute schizophrenia. However,
this is a small study, which is still highly preliminary.
Clearly, a properly powered and controlled trial is
needed to confirm whether this is a constructive
strategy. It is also useful to consider whether an
augmentation effect may occur with atypical
antidepressants rather than with haloperidol. The
authors review the results of eight previous studies,
involving a total of 130 subjects, in which the efficacy
of valproate was evaluated in the treatment of
schizophrenia. However, only one of these, involving
six patients, used specific diagnostic entry criteria and
had a double-blind design. The authors suggest that it
is a GABAA agonism that is the vital component, since
other GABAA agonists, such as benzodiazepines, have
been shown to relieve schizophrenic symptoms in a
dose-dependent manner, whereas GABAB agonists
have not. The authors did not measure haloperidol
levels to see whether there was any pharmacokinetic
explanation for their findings – not least because of
the effect of valproate on liver enzymes; this should
be added to future study design.
Address for reprints: A Wassef, Room 2B-50, University of Texas
Health Sciences Center at Houston-Harris County Psychiatric Center,
2800 South MacGregor Way, Houston, TX 77021, USA.
Comparative evaluation of conventional and novel
antipsychotic drugs with reference to their subjective
tolerability, side-effect profile and impact on quality
of life
Voruganti L, Cortese L, Oyewumi L et al.
Schizophr Res 2000;43:135–45. 
One of the selling points of the new atypical
antipsychotic drugs is that patients are supposed to
prefer them. However, outside of clinical trials, there is
little actual assessment of whether this is in fact the
case. Hence, this study was designed to compare the
effectiveness of conventional and novel antipsychotic
drugs, primarily from a patient’s perspective. The
authors recruited 230 patients with schizophrenia who
had been stabilized on an antipsychotic drug for at
least 6 months (the drug being at the convenience of
the treating physician). Based on the type of
antipsychotic drug therapy received at the time of the
survey, patients were grouped into five categories:
typical antipsychotics (n=44), risperidone (n=50),
olanzapine (n=48), quetiapine (n=42) and clozapine
(n=46). Patients filled in a number of questionnaires,
and clinician ratings were also made. Thus, the
investigators obtained measures of clinical symptom
profiles, subjective responses and attitudes towards
drugs, and the prevalence of dysphoria, akathisia,
abnormal involuntary movements, Parkinsonian
symptoms, and quality of life.
Patients receiving novel antipsychotics experienced
fewer side effects, reported positive subjective
responses and favourable attitudes towards their
treatment, and revealed a lower prevalence of
neuroleptic dysphoria. The differences were
statistically significant (p<0.05) in the risperidone,
olanzepine and quetiapine groups, but failed to reach
significance in the clozapine group, however, this
probably reflects selection bias. Patients receiving
novel antipsychotics also had significantly greater self-
rated improvements in quality of life. Clinician-rated
measures of psychosocial functioning and quality of
life, however, did not reveal any significant differences
between the conventional and novel antipsychotic
drug groups. There were no statistically significant
differences identified between groups of patients
receiving different new antipsychotics, on any of the
variables measured. 
This study is constructive in that it uses a
naturalistic design of ‘normal’ patients outside a
clinical trial. It also suggests that clinician-rated
measures of quality of life may be under-reporting the
subjective improvement patients feel when taking
atypical antipsychotics. These findings may be
valuable when designing future studies of the effects
of new drugs on quality of life in schizophrenia.
Address for reprints: L Voruganti, London Psychiatric Hospital, 850
Highbury Avenue, London, Ont. N6A 4H1, Canada.
Ritanserin as add-on medication to neuroleptic
therapy for patients with chronic or subchronic
schizophrenia
Den Boer JA, Vahlne J-O, Post P et al.
Hum Psychopharmacol Clin Exp 2000;15:179–89. 
Several theories have been proposed as to what, if any,
are the common neurochemical effects of the atypical
antipsychotics. One prominent shared characteristic of
the atypicals is 5-HT2 receptor antagonism. Since there
is also some evidence of increased 5-HT2 receptor
sensitivity in schizophrenic patients, attention has been
directed towards this 5-HT2 receptor antagonism. A
further theory is that it is a combination of D2
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antagonism and 5-HT2 antagonism that is important.
Thus, a logical step from this is to see whether the
addition of a 5-HT2 antagonist to typical antipsychotics
with D2 antagonism will lead to a similarly improved
efficacy as seen with some atypical neuroleptics.
In this international, double-blind, parallel-group
study, the effect of ritanserin, a selective 5-HT2A/2C
receptor antagonist, as add-on medication to an
established neuroleptic therapy in patients with
schizophrenia was compared with that of placebo.
Included patients needed to have chronic or
subchronic schizophrenia according to DSM-IIIR and
to have been treated for at least 3 months with
typical antipsychotics. From a total recruitment of 160
patients, 82 were randomly assigned to treatment
with ritanserin (10 mg once daily) and 78 to placebo
for 8 weeks. Efficacy was evaluated using the Positive
and Negative Syndrome Scale for Schizophrenia
(PANSS). The Clinical Global Impression (CGI) scale
was also completed, for assessment of the overall
severity of illness and for the overall improvement
since baseline. Parkinsonian symptoms were
evaluated by means of the Extrapyramidal Symptom
Rating Scale.
There were no significant differences between the
two treatment groups with respect to demography and
baseline disease characteristics. After 8 weeks’
treatment, the numbers of patients with clinical
improvement on the PANSS negative subtotal and the
total PANSS were higher under placebo than under
ritanserin, but the differences were not statistically
significant. The CGIs of overall severity of
schizophrenia were better under placebo than under
ritanserin (p=0.15 at endpoint). Adverse experiences,
the effects on extrapyramidal symptoms and the use of
antiparkinson medication, were comparable in the two
treatment groups.
The authors accept that the study is resoundingly
negative and discuss reasons why this could be. They
note that many of the patients included in this trial
were severely ill and perhaps treatment-resistant. They
detail possible pharmacokinetic explanations for the
trend towards placebo being more effective. They also
note the possibility that 10 mg is the incorrect dose,
given previous studies showing benefit from 20–30
mg, and draw attention to the heterogeneous nature
of the group and the wide range of neuroleptics that
were being prescribed. Nevertheless, within the
confines of the naturalistic study design, this study
gives a clear answer to the question asked and
suggests ritanserin is not useful in chronic
schizophrenia.
Address for reprints: JA Den Boer, Graduate School for Behavioural
and Cognitive Neuroscience, Dept. of Biological Psychiatry, Academic
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Longitudinal comparative study of risperidone and
conventional neuroleptics for treating patients with
schizophrenia
Bouchard R-H, Mérette C, Pourcher E et al.
J Clin Psychopharmacol 2000;20:295–304. 
These authors used a naturalistic setting to try and
further delineate what happens with antipsychotics in
real life. They conducted a 12-month multicenter study
comparing the effectiveness of risperidone with that of
conventional neuroleptics in patients with chronic,
severe, stabilized schizophrenia who had shown a
suboptimal response to conventional neuroleptics.
A total of 184 patients meeting DSM-IV criteria for
schizophrenia were randomized to either a conventional
neuroleptic (decided according to the preference of the
clinician) or to risperidone. Dosing was flexible
according to clinical judgement. The assessments were
carried out in an open fashion without blinding by the
investigators. Subjects randomized to risperidone were
switched back to a conventional neuroleptic if they
could not tolerate risperidone.
Nine subjects dropped out before the 3-month
assessment and were consequently not considered in
any analyses. A further 10 subjects included in the
analysis dropped out before the end of the study.
Three designs were used when analyzing the results:
an intention-to-treat (ITT) design (in which those
initially randomized to risperidone but switched back to
conventional neuroleptics were included in the
risperidone group), a last-observation-carried-forward
design (which added to the ITT design the dropouts
from both groups) and a No ITT design (which
excluded switches and dropouts from both groups).
However the analysis was done, risperidone showed a
greater effect than conventional neuroleptics on total
symptoms and both positive and negative subscales. At
12 months, the proportion of good responders in the
risperidone group was significantly greater than that
among patients receiving conventional neuroleptics
(30% vs. 15%; p=0.03). Interestingly, the decrease in
baseline psychopathology was highest in the lower
dosage range for both risperidone and conventional
neuroleptics, of course, this may well be reverse
causality, in that for those who were poor responders
the dose was increased. Furthermore, the data
suggested that negative symptoms and general
psychopathology improved early in response to
risperidone, whereas the maximal superiority of
risperidone for treating positive symptoms did not
appear until 6 to 12 months after commencement of
dosing. Thus, within the confines of a naturalistic
study, it may be that lower doses over longer periods
are needed. The authors also discuss the careful
method with which they crossed patients over from
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conventional neuroleptics to risperidone, which they
believe facilitated a high compliance rate.
One caveat of the study is the lack of blinded
assessments. The addition of such — although involving
extra complexity and expense — would strengthen the
validity of findings in future naturalistic studies.
Address for reprints: RH Bouchard, Polyclinique Sainte-Anne,
65 Sainte Anne, Quebec, Que. G1R 3X5, Canada.
Recent patterns and predictors of antipsychotic
medication regimens used to treat schizophrenia and
other psychotic disorders
Wang PS, West JC, Tanielian T et al.
Schizophr Bull 2000;26:451–7.
The authors used data from the 1997 American
Psychiatric Association (APA) Practice Research
Network (PRN) Study to identify the prescribing
patterns of antipsychotics, as well as the factors
associated with the use of particular regimens.
Psychiatrists participating in the PRN Study consisted
of 224 randomly recruited individuals and 307 self-
identified volunteers, generally representative of APA
members. Information for this study was provided by
the 417 (78%) PRN psychiatrists who provided
patient-level data on 1245 patients. All were asked to
complete a detailed diagnostic and treatment form for
three patients who had been randomly preselected on
a patient log. All analyses of psychopharmacologic
treatment in this study were conducted among the 154
patients diagnosed as having schizophrenia or
schizophreniform, schizoaffective, shared psychotic, or
psychotic disorders not otherwise specified.
Nearly all patients (95%) were being treated with at
least one antipsychotic at the time of the survey, 15%
were receiving two antipsychotics concurrently, and 2%
were receiving three or more. Possible reasons for this
polypharmacy include a perceived greater effectiveness
by the prescriber or a difficulty in completing titration.
Overall, 24% of patients were receiving risperidone,
23% olanzapine, and 7% clozapine. Multiple logistic
regression analysis showed that factors associated with
being prescribed newer antipsychotics included being
elderly, having psychiatric comorbidity, making fewer
visits to the psychiatrist in the prior month, having more
education, and being white.
Several hypotheses were suggested to explain the
above associations. It is possible that atypicals are
prescribed to the elderly because of concerns regarding
their vulnerability to side effects. Prescribers may also
consider atypicals safer in patients with comorbidity
but not in patients in acute relapse, hence the
association between fewer psychiatric consultations
and being on an atypical. The findings regarding race
and education may reflect prescriber bias, or the
patients’ ability to advocate successfully for atypicals
the better their education and socioeconomic status.
Other factors such as differences in illness severity or
vulnerability to side effects cannot be excluded. Finally,
the associations between patients’ features and use of
newer antipsychotics might have arisen by chance
because of the multiple comparisons employed in the
study. Other methodological limitations include the
study’s cross-sectional nature, the relatively small
sample size, and the issue of whether PRN Study
psychiatrists and patients are indeed nationally
representative. However, the development of data
sources such as this one, containing empirical data on
patterns, predictors and outcomes of treatment, are
important for clinical and policy decision making in the
treatment of patients with schizophrenia.
Address for reprints: PS Wang, Div. of Pharmacoepidemiology and
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Dr Vogely highlighted the fact that, whilst research
had identified pathology within several regions,
including the frontal, temporal and limbic cortex, it had
failed to identify a single site of brain pathology
underlying schizophrenia. This suggested the
disturbance of a wider network involving different brain
structures. He reviewed the data from the most likely
candidates, the fronto-temporal and fronto-parietal
connections, using functional MRI and post-mortem
data to demonstrate the disruption of the normal
relationships between these regions. KJ Friston (London,
UK) offered a theory from a theoretical neurobiology
perspective, with the intention of bridging the gap
between clinical symptoms and the neuronal and
neurochemical systems. He put forward a hypothesis
that schizophrenia arose as a result of dysfunctional
integration amongst different neuronal systems within
the brain. The pathophysiology of schizophrenia was
expressed at the level of modulation of associative
changes in synaptic efficacy; specifically the modulation
of plasticity in those brain systems responsible for
emotional learning in memory. He went on to suggest
that this modulation is mediated by neurotransmitters
that are implicated in schizophrenia and are known to be
involved in consolidating synaptic connections during
learning. Failure of this synaptic connectivity would
result in disruption and failure of the reinforcement of
adaptive behavior, which would give results consistent
with the neuropsychological findings evident in
schizophrenia, consisting of subtle memory and
executive functioning deficits. These neuropsychological
deficits would impair the normal processes involved with
self-awareness and language processing to culminate in
the clinical symptoms seen in schizophrenia, such as
hallucinations and delusions. The studies presented at
the symposia suggested that the emphasis on future
schizophrenia research should be placed on examining
the connectivity or relationship between different brain
regions rather than concentrating on more of the
‘lesion-based’ models of the disorder. 
This conference brought together approximately 2500
academics and clinicians from across Europe. Prague
provided an ideal backdrop, sheltered from the adverse
weather conditions in Western Europe and the
sweltering political climate in the USA. An unusual
group of attendees were the protesters barracking
outside the meeting, holding banners asking for
psychiatrists to view patients as individuals rather than
syndromes. The meeting covered a diverse range of
topics organized by the various sections of the
Association of European Psychiatry, with some cross-
disciplinary symposia. However, the symposia relevant
to this readership were predominantly based on the
conceptualization and treatment of schizophrenia. 
The (dys)connectivity hypothesis of schizophrenia
One of the challenges for schizophrenia research is to
link the research findings from the broad
range of neurochemical, neuroanatomical and
neuropsychological studies and the clinical symptoms
encountered in daily clinical practice. One traditional
approach has been to compare regional brain changes
in schizophrenic patients and controls. E Ceskova (Brno,
Czech Republic) presented data on first-episode
inpatients with schizophrenia, and used structural MRI
to compare the temporal lobes of patients and controls.
Significant decreases were reported in the linear
measurement of hippocampal complex, and
were greater on the right side. However, the
decrease in hippocampal cortex was not significantly
correlated with the treatment outcome. K Vogeley
(Bonne, Germany) reviewed some wider
methodological considerations examining how
contemporary schizophrenia research is using the
following two approaches:
• examining psychopathological syndromes as
secondary to core neuropsychological deficits 
• examining localized organic brain changes, as in the
above study, within certain candidate regions. 
10th Congress of the Association of
European Psychiatrists
Prague, Czech Republic, October 28–November 1, 2000 
Sukhi S Shergill 
Institute of Psychiatry, London, UK
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Treatment 
The usefulness of the atypical antipsychotic drugs is no
longer in any doubt; the next challenge appears to lie in
the selection of the optimal medication for the patient’s
symptom profile. P Mohr (Prague, Czech Republic)
presented data on a prospective, double-blind,
randomized, 14-week trial in which 157 treatment-
resistant inpatients diagnosed with chronic schizophrenia
or schizoaffective disorder were assigned to treatment
with either clozapine, olanzapine, risperidone or
haloperidol. The 14 weeks of the trial were divided into
an initial 8-week escalation up to a fixed-dose period,
and a later 6-week period where the dose could be
adjusted. In the initial phase, the doses were escalated to
500 mg clozapine, 20 mg olanzapine, 8 mg risperidone
and 20 mg haloperidol per day. The data demonstrated
that clozapine, olanzapine and risperidone resulted in
statistically significant improvements on the total
Positive and Negative Syndrome Scale (PANSS) score
during the first period. Clozapine and olanzapine were
more effective against negative symptoms than
haloperidol, and these differences were not mediated by
extrapyramidal side effects. A more clinically based study
was presented by L Conlan (Galway, Ireland), who
performed a clinical audit of patients prescribed depot
neuroleptics (143 patients on depot medication in a
service area of approximately 100 000 population).
Thirty-three patients were identified who consented to
changing their medication to oral risperidone (out of a
total of 69 who were eligible). Twenty-three of these
completed 6 months of treatment with risperidone, and
all were reported as having a good outcome. Nineteen
of these patients were still taking risperidone after
12 months. Of the patients who dropped out in the first
6 months, only one showed insufficient response, the
others were related to non-compliance (n=4) and
adverse advents (n=3). They suggested that
approximately half of the patients with chronic
schizophrenia receiving depot neuroleptics would do
well when switched to oral risperidone.
M Yu Popov (St Petersburgh, Russia) presented
a study of 30 first-admission inpatients with a
diagnosis of DSMIV schizophrenia who were
randomly assigned to 3 weeks of double-blind
treatment with clozapine (n=20) or haloperidol
(n=10). Dr Yu Popov demonstrated that clozapine
produced significantly greater improvements on both
the Brief Psychiatric Rating Scale (BPRS) and the
Clinical Global Improvement scale (CGI). Eighty-five
percent of the patients responded to clozapine,
whereas only 50% demonstrated a response to
haloperidol (clinical response defined as a decrease of
30% in the total BPRS). They also showed that, whilst
the total number of reports and adverse events did
not differ between the groups, the severity was
graded as lower in the clozapine group. There were no
cases of agranulocytosis during their study. This is an
unusual study in that clozapine is only available for
treatment-resistant schizophrenia in most other
countries. A study that examined patients’ satisfaction
with their medication was presented by G Bartko
(Budapest, Hungary), with data from 74 chronic
patients with DSMIV schizophrenia who had been
switched to an atypical antipsychotic (either
risperidone, olanzapine or quetiapine) after having
either failed to respond to conventional antipsychotics
or suffered adverse side effects. They completed a
patient satisfaction questionnaire after 3 months of
being treated with the atypical antipsychotic and
reported that 60% of patients evaluated the new
treatment as better than the previous treatment, 83%
wished to continue this treatment and over half the
patients were fully or very satisfied with the new
medication. There was no relationship between
satisfaction with treatment and clinical improvement.
This supports a conceptual model for patient
satisfaction, where satisfaction is influenced by factors
other than clinical improvement. This study also
provides some support for improved compliance with
the atypical antipsychotic drugs. 
